WO2020148347A1 - Ag2s nanoparticles and methods of production thereof - Google Patents

Ag2s nanoparticles and methods of production thereof Download PDF

Info

Publication number
WO2020148347A1
WO2020148347A1 PCT/EP2020/050939 EP2020050939W WO2020148347A1 WO 2020148347 A1 WO2020148347 A1 WO 2020148347A1 EP 2020050939 W EP2020050939 W EP 2020050939W WO 2020148347 A1 WO2020148347 A1 WO 2020148347A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
ag2s
silver
dots
superdots
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/050939
Other languages
French (fr)
Inventor
Jorge Rubio Retama
Diego MÉNDEZ GONZÁLEZ
Marco Laurenti
Daniel Jaque García
Harrison David ASSIS SANTOS
Erving C. XIMENDES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Universidad Autonoma de Madrid
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal
Original Assignee
Universidad Complutense de Madrid
Universidad Autonoma de Madrid
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid, Universidad Autonoma de Madrid, Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal filed Critical Universidad Complutense de Madrid
Publication of WO2020148347A1 publication Critical patent/WO2020148347A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00Sulfur; Compounds thereof
    • C01B17/20Methods for preparing sulfides or polysulfides, in general
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01GCOMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G5/00Compounds of silver
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/08Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials
    • C09K11/58Luminescent materials, e.g. electroluminescent or chemiluminescent containing inorganic luminescent materials containing copper, silver or gold
    • C09K11/582Chalcogenides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/80Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/82Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by IR- or Raman-data
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/80Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/84Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/80Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/85Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by XPS, EDX or EDAX data
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/01Particle morphology depicted by an image
    • C01P2004/04Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/60Particles characterised by their size
    • C01P2004/64Nanometer sized, i.e. from 1-100 nanometer

Definitions

  • the present invention refers to the biomedical field, in particular to nanoparticles for use as imaging fluorescent agents for in vitro and in vivo applications.
  • NIR-II near infrared window
  • both tissue absorption and scattering coefficients are reduced to a minimum, allowing high-contrast, high-resolution in vivo imaging at large (> 1 cm) tissue depths9.
  • NIR-II fluorescent semiconductor nanocrystals have changed the game in preclinical fluorescence imaging, enabling previously unthinkable feats such as high-resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes.
  • NIR-II emitting Ag S nanocrystals are free from heavy metal ions, unlike other nanoprobes operating in this spectral range, minimizing biocompatibility concerns and making them the most promising system among all currently reported NIR-II fluorophores.
  • Their properties have been exploited for multiple applications, including subcutaneous and transcranial thermometry 16, in vivo heart imaging, [https://doi.org/10.1007/s12274-019-2280-4.], photoacoustic imaging, [https://doi.org/10.1021/acsnano.6b07866], theranostics [https://doi.org/10.1007/s12274-018-2210-x], tumour diagnosis and dynamic imaging of the cardiovascular system.
  • the present invention demonstrates the crucial role of the synthetic conditions on the photoluminescence properties of Ag S nanoparticles. More in detail, the effect of the solvent ratio of DDT and OLA during the nanoparticle generation via thermal degradation using an Ag(DDTC) was evaluated. In total, six different solvent ratios were tested (X DDT of 0.00, 0.15, 0.30, 0.60, 0.90 and 1.00). From a structural point of view, a clear decrease in nanoparticle size with an increase of DDT was observed, assumingly correlated to a more pronounced stabilization of small nanoparticles by the thiol bearing solvent DDT.
  • a first aspect of the invention refers to a method for manufacturing, preferably hydrophobic, Ag S nanoparticles comprising the following steps:
  • a solvent comprising a mixture based
  • the solvent mole fraction (xDDT) is between 0.45 and 0.75. More preferably, the solvent mole fraction (xDDT) is between 0.55 and 0.65. More preferably, the solvent mole fraction (xDDT) is between 0.58 and 0.62. Still more preferably, the solvent mole fraction (xDDT) is between 0.59 and 0.61. Still more preferably, the solvent mole fraction (xDDT) is between 0.595 and 0.605. Still more preferably, the solvent mole fraction (xDDT) is between 0.598 and 0.602. Still more preferably, the solvent mole fraction (xDDT) is between 0.599 and 0.601- Still more preferably, the solvent mole fraction (xDDT) is about 0.60. Still more preferably, the solvent mole fraction (xDDT) is 0.60.
  • silver in any form such as those selected from the list consisting of: Ag(DDTC), silver nitrate, silver dihydrocarbyl thiophosphate, silver dioctyl sulfosuccinate, silver thiobenzoate, silver acetate, silver dodecanoate, silver tetradecanoate and silver octadecenoate.
  • the organic long- chain molecules are selected from the list consisting of octylamine, trioctylamine, dodecylamine, octadecylamine, and OLA (oleylamine).
  • OLA oleylamine
  • such molecule is and OLA (oleylamine).
  • the closed atmosphere is created by using a vacuum, preferably for about 10 min, to remove air and then filled with N , other inert gases like Argon, or He can be also used.
  • step b) the mixture is heated to a temperature between 120°C and 350°C, preferably between 150°C and 230°C, more preferably between 170°C and 210°C, still more preferably to a temperature about 190°C, under magnetic stirring, preferably with a heating rate of 20°C/min and under slow magnetic stirring.
  • step c) prior to step c) the reaction is cooled down by any suitable means, preferably by naturally cooling the reaction.
  • the nanoparticles are preferably collected by the addition of ethanol, which reduces the colloidal stability of the nanoparticles, preferably by adding about 10 mL of ethanol to the raw product and centrifuging at about 10,000 rpm for 10 min, and preferably repeating this process twice.
  • the resultant product of step c) is dispersed in chloroform and stored.
  • a second aspect of the invention refers to a method for manufacturing pegylated hydrophobic Ag S nanoparticles comprising the following steps:
  • a hydrophilic agent such as 11-mercaptoundecanoic acid (MUA), dihydrolipoic acid, 2,3 dimercaptosuccinic acid, mercaptopropionic acid, or cysteine, to a dispersion containing Ag S/Ag nanoparticles as obtained from the method of the first aspect of the invention, preferably in chloroform at room temperature; b. Precipitating and collecting the product of step d);
  • a hydrophilic agent such as 11-mercaptoundecanoic acid (MUA), dihydrolipoic acid, 2,3 dimercaptosuccinic acid, mercaptopropionic acid, or cysteine
  • step e) Covering the precipitates of step e) with PEG, preferably PEG-NH 2 , more preferably via EDC/NHS coupling; and
  • the precipitating step e) is performed by sonicating the mixture in an ultrasonic bath, preferably for 10 minutes, until the Ag 2 S/Ag nanoparticles lose their colloidal stability and precipitate.
  • the treatment with PEG via EDC/NHS coupling in performed by dissolving EDC and sulfo-NHS in a saline solution such as PBS comprising the nanoparticles obtained from step e) and PEG.
  • a third aspect of the invention refers to, the preferably hydrophobic, Ag 2 S nanoparticles obtained or obtainable by the method of the first aspect of the invention or of any of its preferred embodiments.
  • a fourth aspect of the invention refers to pegylated Ag 2 S nanoparticles obtained or obtainable by the method of the second aspect of the invention or of any of its preferred embodiments.
  • a fifth aspect of the invention refers to a composition comprising the hydrophobic Ag 2 S nanoparticles of the third aspect of the invention.
  • a sixth aspect of the invention refers to a composition comprising the pegylated hydrophobic Ag 2 S nanoparticles of the fourth aspect of the invention.
  • a seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use as an in vivo imagining agent, or for in vivo fluorescence imaging, enabling features such as high-resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes.
  • a further application of the seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use in vivo diagnosis.
  • a further application of the seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use in in vitro diagnosis as a imagining agent, in particular as a fluorescence imaging agent.
  • example 2 A second part of the present invention, is shown in example 2, which demonstrates the potential of femtosecond laser pulses to radically improve the properties of luminescent nanostructures operating in the second biological window.
  • the capacity of ultrafast laser irradiation to tune the structural and optical properties of infrared luminescent Ag S NPs shown here can undoubtedly expand their range of applications, especially in the field of nanomedicine.
  • Our discovery the ability of ultrafast laser pulses to improve the luminescent properties of nanoparticles, also stimulates new synthesis procedures that could benefit from the synergy between traditional chemical procedures and light-matter interaction processes.
  • a second part of the present invention relates to hydrophobic Ag S nanoparticles capable of emitting in the near infrared with a quantum efficiency of 10% (representing a 50-fold increase with respect to the efficacy of the nanoparticles obtained so far) as well as to a method of synthesis of the same.
  • Such nanoparticles can be superficially functionalized, making them especially suitable as imaging contrast agents in biological applications.
  • an eight aspect of the invention refers to a method of manufacturing, preferably, hydrophobic Ag S nanoparticles comprising the following steps: a. Mixing a given amount of silver with a long chain organic molecule, preferably having between 4 and 20 carbons in length, comprising an amine group;
  • a polar organic solvent is added to the mixture, centrifuged and the obtained nanoparticles are washed giving rise to the hydrophobic nanoparticles that are collected in step c).
  • silver is provided by using one or more molecules selected from the list consisting of: silver nitrate, Ag(DDTC) (silver diethyldithiocarbamate), silver dihydrocarbyl thiophosphate, silver dioctyl sulfosuccinate, silver thiobenzoate, silver acetate, silver dodecanoate, silver tetradecanoate and silver octadecanoate.
  • DDTC silver diethyldithiocarbamate
  • silver dihydrocarbyl thiophosphate silver dioctyl sulfosuccinate
  • silver thiobenzoate silver acetate
  • silver dodecanoate silver tetradecanoate
  • silver octadecanoate silver octadecanoate
  • the organic long- chain molecules are selected from the list consisting of octylamine, trioctylamine, dodecylamine, octadecylamine, and OLA (oleylamine).
  • the nanoparticles of the eight aspect of the invention, or the nanoparticles of the first or second aspects of the invention are treated with an ultra-fast laser treatment, wherein such treatment is performed by dispersing the Ag S nanoparticles in chloroform, dichloromethane, dichloroethane, trichloroethane or in any organic solvent comprising chlorine; and wherein such nanoparticles may be optionally further subjected to a ligand exchange reaction to generate hydrophilic Ag S nanoparticles.
  • the ion exchange reaction is carried out by mixing hydrophobic Ag S nanoparticles with an equivalent amount or an excess amount of a hydrophilic molecule comprising a thiol group so that the surface of the Ag S nanoparticles are functionalized by the hydrophilic group thus obtaining or resulting in hydrophilic particles.
  • the hydrophilic molecule is selected from the group consisting of: mercaptoacetic acid, mercaptopropionic acid, cysteine, cysteinamine, thioctic acid, ammonium mercaptoacetate, or any combination thereof.
  • the laser treatment is performed by dispersing the Ag S nanoparticles in chloroform.
  • ultra-fast laser is understood as any laser capable of producing laser pulses with a temporal duration below 500 femtoseconds.
  • the ion exchange ligand reaction of the ninth aspect of the invention can be carried out by mixing hydrophobic Ag S nanoparticles with an equivalent amount or an excess amount of a hydrophilic molecule that contains a thiol group, in an organic solvent such as ethanol, methanol, acetone, chloroform, dichloromethane, toluene, 1- methyl-2-pyrrolidone or any combination thereof, at a temperature between 0 and 80°C for a period of about 1 hour or more.
  • the reaction time can be modified according to the reactivity and solubility of the stabilizing molecule.
  • the pH of the aqueous solutions used during this reaction should be between 7 and 14.
  • the nanoparticles are preferably washed with an aqueous solution to remove any residues.
  • the ultra-fast laser shall be applied for a period of time that will depend on the specific characteristics of the laser, among which are: wavelength, pulse length, frequency, applied power density and beam diameter size.
  • the ultrafast laser treatment of the ninth aspect of the invention induces a structural change that eliminates defects and increases the quantum efficiency of the nanoparticles. This process is preferably performed by dispersing the Ag S nanoparticles in chloroform, dichloromethane, dichloroethane, trichloroethane or any organic solvent containing chlorine.
  • the nanoparticles are irradiated using an ultra-fast laser at a wavelength, preferably between 200 and 1000 nm, more preferably between 300 and 900 nm, more preferably between 400 and 800 nm, still more preferably about 800 nm; with a power density of less than 40W/cm 2 , preferably between 3 and 30 W/cm 2 , more preferably between 6 and 10 W/cm 2 , still more preferably about 9 W/cm 2 ; with pulses of less than 500 femto-seconds, preferably with pulses of about 50 femto-seconds; and at preferably a frequency of 1 kHz for preferably approximately 10 minutes.
  • a wavelength preferably between 200 and 1000 nm, more preferably between 300 and 900 nm, more preferably between 400 and 800 nm, still more preferably about 800 nm; with a power density of less than 40W/cm 2 , preferably between 3 and 30 W/cm 2 , more preferably between
  • a tenth aspect of the invention refers to Ag S nanoparticles obtained or obtainable by the method of the ninth aspect of the invention or of any of its preferred embodiments.
  • An eleventh aspect of the invention refers to a composition comprising the Ag S nanoparticles of the tenth aspect of the invention.
  • a twelft aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use as an in vivo imagining agent, or for in vivo fluorescence imaging, enabling features such as high- resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes.
  • a further application of the twelfth aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use in vivo diagnosis.
  • a further application of the twelfth aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use in in vitro diagnosis as a imagining agent, in particular as a fluorescence imaging agent.
  • FIG. 1 HAADF-STEM micrograph of nanoparticles obtained under different synthetic conditions (from A1 to F1).
  • the insets from A2 to F2 represent the EDS elemental mapping of silver while the insets from A3 to F3 depict the EDS elemental mapping of sulfur.
  • From A4 to F4, merged figures resulting from the HAADF-STEM and EDS elemental analysis are showed.
  • the insets from A5 to F5 show detailed magnifications of the merged EDS and HAADF-STEM micrographs.
  • Figure 4 A) Normalized UV-Vis spectra of the nanoparticles synthesized under different solvents ratios.
  • Inset A1 shows the absorbance change as a function of the wavelength.
  • Insets B1 and B2 show the variation of the maximum of the emission wavelength and the maximum of the PL intensity as a function of the solvent ratio.
  • the color legend is as follows: Ag 2 S-0.00 cyan, Ag 2 S-0.15 red, Ag 2 S-0.30 green, Ag 2 S-0.60 blue, Ag 2 S-0.90 orange, Ag 2 S-1.00 black, with numeric values indicating the XDDT.
  • EDS-mapping profile of the Ag S/Ag nanoparticles (A, D and G. Net X-ray profile extracted from the yellow arrow marked in the STEM images (B, E, and H). Merged STEM and nanoparticles model images represented as a function of Ag/S ratio versus the probe position (B, E and H). Frequency distribution of the Ag/S ratio in the nanoparticles excluding the silver core (C, F and I). The nanoparticles used for EDS- mapping were derived using X DDT of 0.00 (A-B), 0.60 (D-F) and 1.00 (G-l) during synthesis.
  • Figure 6 A) Schematic representation for the surface modification of the nanoparticles by ligand exchange reaction with MUA and its subsequent PEGylation through EDC/sulfo-NHS coupling reaction.
  • FIG. 7 A) In vivo imaging of an anesthetized mouse 5 min after intravenous injection of the here optimized Ag2S nanoparticles. The animal was optically excited with an 800 nm laser diode and luminescence (1000-1400 nm) was recorded with an infrared camera. B) Magnification of the lower extremities where the femoral vessels can be observed. C) A cross-sectional intensity profile measured along the black dashed line in (B). D) ex vivo NIR-II image of dissected mouse of the skeleton E) lung spleen and liver and F) detailed image of femur, tibia, ilium, and sacrum of mice.
  • Figure 8 (a) TEM image of the as synthesized Ag2S/Ag nanoparticles (b) HR-TEM of a single electrodense nanoparticle, showing its polycrystalline structure with lattice fringe 0.20 and 0.23 nm. (c) HAADF-STEM image of the as synthesized Ag S/Ag nanoparticles
  • Figure 10 (a) and (b) are HAADF-STEM image of Ag S dots and superdots, respectively (c) and (d) show the size distributions of Ag S dots and superdots, respectively. Orange and red bars correspond to size distribution of Ag core and whole NP, respectively (e) Schematic representation of the structure ofAg S dots. The average sizes of whole nanoparticle and Ag core are indicated (f) Schematic representation of the structure of Ag S superdots, including the sizes. The average sizes of whole nanoparticle and Ag core are indicated. Figure 11.
  • the inset shows a model nanoparticle (h) HAADF-STEM micrograph of Ag2S dots after ultrafast laser irradiation with 50 fs laser pulses for 90 min and with a power density of 9 W/cm2.
  • FIG. 12 (a) XRD pattern of the as synthesized Ag2S dots sample. The red lines represent typical reflections of monoclinic Ag2S phase, whilst green lines represent the reflection positions of cubic Ag. (b) XANES spectra of Ag2S dots (red) and Ag2S used as reference (blue) and Ag foil used as reference (black) (c) EDS spectrum of Ag2S dots (d) EDS elemental mapping of Ag2S, silver (yellow), sulphur (red), the inset in the bottom left is the resulting image after merging S+Ag and the inset in the bottom right is the HAADF-STEM image from which the EDS map was collected. The scale bar is 10 nm. Figure 13.
  • FIG. 14 Optical transformation of Ag2S dots into superdots
  • the dispersions were optically excited with an 808 nm continuous wave laser diode (100 mW/cm 2 ).
  • the inset shows the normalized emission spectra of the sample before and after the laser irradiation
  • Error bars correspond to the standard deviations as obtained by measuring and analysing up to 10 decay curves for each sample.
  • squares and circular points refer to the experimental data and the red lines are guides for the eyes.
  • Figure 15 (a) VIS-NIR extinction spectra of colloidal dispersions of Ag S dots in CHCh after ultrafast laser irradiation for different times (b) Extinction coefficient at 400 nm as a function of the ultrafast laser irradiation time, obtained from the spectra shown in (a) (c) Extinction coefficient at 808 nm as a function of the ultrafast laser irradiation time, as obtained from (a) (d) Fluorescence decay curves of colloidal dispersions of Ag2S dots in CHCh after ultrafast laser irradiation for different times. In all cases, the dispersions were treated with an ultrafast laser with the same pulse width, power density (50 fs, 9 W/cm 2 ).
  • FIG 16. Illustrative examples of the spectra used for the determination of the QY.
  • Data correspond to dispersions of Ag S dots and superdots in CHCh and in PBS.
  • the spectra of the excitation light (808 nm) is measured with and without sample. From the difference between these spectra, the number of absorbed photons is calculated in each case. The number of emitted photons generated by each sample is calculated from the emission spectra recorded in presence of the sample. Then, the QY is calculated by dividing the number of emitted photons by the number of absorbed photons. All the emission spectra are corrected by the system response.
  • Figure 17 Required conditions and mechanisms of laser induced dot-to-superdot transformation
  • Figure 18 (a) Optical images and (b) NIR-II emission intensity for a dispersion of Ag2S in CHCh after a 100-minute-long ultrafast laser irradiation at different power densities.
  • Figure 19 In vivo brightness of Ag2S superdots: a comparison with their competitors (a) NIR-II fluorescence decay curves of PEG-coated Ag2S dots (provided by Sinano Corp., China) and Ag2S superdots, both dispersed in PBS.
  • Ag2S superdots enable the use of illumination power densities almost two orders of magnitude below those required for imaging with other NIR-II probes
  • FIG. 20 In vivo time-resolved imaging with Ag2S superdots
  • c NIR-II ex vivo fluorescence and optical images of the liver, spleen, heart and lungs.
  • the mouse was euthanized 100 min after intravenous injection of Ag2S superdots (d) Time evolution of daily food intake (e) weight and (f) body temperature of CD1 mice after intravenous injection of 300 pL of a dispersion of Ag2S superdots in PBS (0.5 mg/mL, leading to a total dose of 150 pg of Ag2S superdots).
  • mice intravenously injected with 300 pL of PBS were included for comparison
  • (j)-(k) Serum concentration of creatinine and bilirubin corresponding to mice subjected to an intravenous injection of Ag2S superdots and for control mice as obtained 1 and 28 days after injection. (n 3 for each group). Error bars corresponding to standard error of the mean ⁇ SEM.
  • TEM Transmission electron microscopy
  • TEM Talos F200X operated at 80 kV.
  • Zeta-potential experiments were carried out using a Malvern Nano-ZS.
  • the FTIR spectra were obtained using a Nicolet IR200 FTIR spectrometer.
  • the emission spectra upon illuminating the samples with an 800 nm CW laser were collected with an Andor iDus InGaAs 491 cooled to -90°C.
  • the absolute photoluminescence QY was measured with a calibrated spectrofluorometer (Edinburgh Instruments, FLS920) equipped with an integrating sphere (Jobin-Yvon).
  • a Xe lamp has been used as excitation source, filtered with a long- pass filter (610 nm) and a monochromator (wavelength: 800 nm, bandwidth: 20 nm).
  • Luminescence was detected by a liquid nitrogen cooled NIR photo-multiplier tube (Hamamatsu, R5509-72).
  • the QY has been calculated by dividing the total number of emitted photons in the 900-1700 nm range by the total number of absorbed photons at 800 nm.
  • Luminescence decay curves were obtained by exciting the colloidal suspensions of nanoparticles by an OPO oscillator (Lotis) tuned to 800 nm, which provides 8 ns pulses at a repetition rate of 10 Hz. Fluorescence intensity was detected with a Peltier cooled photomultiplier tube with enhanced sensitivity in the NIR-II (Hamamamatsu R5509-73). The contribution of scattered laser radiation was removed by using two band-pass filters (FEL850 from Thorlabs) as well as a high brightness monochromator (Shamrock 320 from Andor). The time evolution of the fluorescence signal was finally recorded and averaged by a digital oscilloscope (LeCroyWaverunner 6000).
  • High-angle annular dark field (HAADF) scanning TEM and EDX mappings were conducted by using a FEI Talos F200X (FEI, USA) coupled to a EDX detector.
  • Samples for TEM were prepared by adding 10 m ⁇ - of each dispersion on a Cu grid with a carbon support membrane, followed by drying.
  • NIR-II in vivo images were obtained in a homemade NIR-II system.
  • a fiber-coupled diode laser operating at 800 nm was used as excitation source (LIM030-F200-DL808).
  • the illumination intensity was controlled via adjustment of diode current.
  • An anesthetized mouse was placed on a homemade temperature-controlled plate operating at 36 °C.
  • the NIR-II fluorescence image was acquired with a Peltier cooled InGaAs camera (Xeva 320 from Xenics).
  • the InGaAs detector was cooled down to -40 °C.
  • Two long-pass filters FEL850 from Thorlabs
  • the mixture was submitted to vacuum for 10 min to remove air and then filled with N2. After that, the mixture was heated to 190°C under magnetic stirring with a heating rate of 20°C/min and under slow magnetic stirring. The reaction was kept for 1 hour and subsequently cooled down naturally.
  • the synthesized nanoparticles were collected by addition of ethanol, which reduces the colloidal stability of the nanoparticles. To do that, 10 L of ethanol were added to the raw product and centrifuged at 10,000 rpm for 10 min, this process was repeated twice. Finally, the as-prepared product was dispersed in 10 mL of chloroform and stored for further steps.
  • Figure 1 depicts HAADF-STEM images of the Ag2S nanoparticles synthesized using different solvent ratios. As observed, all the nanoparticles exhibit two well-differentiated regions, a white area with higher Z-contrast, corresponding to the electrodense parts of the nanoparticles, probably due to the presence of metallic Ag into the nanoparticle. In addition, the figure shows the existence of less electrodense areas that appear as grey regions, corresponding to Ag2S.
  • Figure 4 summarizes the impact of the synthetic conditions on the spectroscopic properties of the nanoparticles (absorption, photoluminescence, lifetime and QY).
  • Figure 4A shows the normalized absorption spectra for all samples in the range between 300 to 900 nm. In all cases, a strong absorption in the visible region with weak shoulder at 465 nm and a long tail until the NIR region can be observed. The shoulder at -465 nm may be attributed to the plasmonic contribution of the metallic Ag present in the nanoparticle. It is important to note that this band only appears in those syntheses in which OLA is used. This indicates the role of the amino groups in the formation of metallic silver during the synthesis of the nanoparticles at high temperatures.
  • alkylamines in the reaction may lower the dissociation energy of the S-C bonds of the silver precursor via nucleophilic addition of an amine to the carbonyl group, thereby potentially providing a higher amount of reactive sulfur in the reaction resulting in an increased Ag S formation.
  • Figure 2 here one can observe the reduction of the size of the Ag S matrix when increasing X DDT , whilst the size of the Ag core remains unchanged.
  • Figure 4B shows the emission band of the different samples as obtained under 800 nm optical excitation.
  • the emission band is clearly affected by the synthesis conditions. Firstly, we observe that the peak wavelength is red-shifted when increasing X DDT .
  • the nanoparticles synthesized only in the presence of OLA exhibit its maximum emission at 1160 nm, whilst those synthesized using only DDT as solvent showed its emission peak at 1220 nm.
  • These variations indicate an increment in the bandgap of the nanoparticles when increasing the X DDT , which cannot be attributed to quantum confinement effects, since the size of all these nanoparticles are well above the Bohr radius of the Ag S.
  • Such a profile creates a rapid increment of the Ag/S atomic ratio from a S enriched surface to a Ag enriched core, giving as a result a very small region where the matrix composition could be Ag 2 S, decreasing the NIR fluorescence of these nanoparticles, as shown in Figure 5H.
  • the frequency distribution of the Ag/S ratio does not permit us to observe any maximum close to 2, which would indicate the presence of a thin Ag 2 S region surrounded by structural defects, which would render Ag 2 S nanoparticles with poor luminescent properties as observed in Figure 5I.
  • carboxylic groups were used as anchoring points, allowing for the linkage of PEG-NH 2 molecules (5 kDa) through the amino terminated group, performing a coupling reaction mediated by EDO and sulfo-NHS.
  • the products of this reaction are PEG- modified nanoparticles with a hydrodynamic diameter of 20 ⁇ 9 nm and a Zeta-potential of -16 mV, which is still negative due to the presence of remaining carboxylate groups on the surface of the nanoparticles that did not react with PEG, as seen in Figure 6.
  • FIG 7A an optical infrared fluorescence merged image of the mouse, as obtained 5 minutes after the injection of the nanoparticles, is shown.
  • a clear luminescence signal is detected at the abdominal area of the mouse which is attributed to a fast accumulation of nanoparticles in the liver.
  • the zoom included in Figure 7B reveals the presence of nanoparticles in the bloodstream. In particular, vessels of the lower limbs are evident in the amplified fluorescence image.
  • the optimized Ag2S nanoparticles are bright enough to provide an image of the vessel anatomy with a sub-millimeter spatial resolution (see intensity profile in Figure 7C).
  • the animal were sacrificed 1 hour after injection and the presence of Ag2S in the different organs was elucidated from their fluorescence images.
  • Figure 7D shows the fluorescence image corresponding to the skeleton, indicating the partial accumulation of Ag S nanoparticles within bones.
  • Figure 7E includes the infrared fluorescence images corresponding to the liver, spleen, and lungs.
  • FIG. 7F shows an amplified fluorescence image of the bone structure of a limb.
  • Ag S nanoparticles are also known to be excellent luminescent nanothermometers. This means that they could be potentially used to measure intra-bone temperature. This, in turns, becomes essential to achieve full control over photothermal therapies of bones, that have been recently demonstrated to be of high efficacy to promote bone regeneration.
  • Ag/Ag S heterodimers (hereafter Ag S dots) were prepared as follows: 3 mmol of silver nitrate was poured into a round bottom flask containing 10 mL of octadecylamine at 160 °C under gentle stirring and N atmosphere. After 10 minutes, the mixture acquired a metallic blue color. At this stage, 1.5 mmol of L-cysteine was added to the mixture as sulphur source. As result, the colour of the mixture turned from blue to black indicating the formation of the heterodimer (30 minutes). Then, the sample was cooled down and the product of the reaction was dispersed in 40 mL of CHCI 3 .
  • the laser provides pulses with a repetition rate of 1 kHz and tunable pulse widths in the 50-550 femtosecond range.
  • the real-time NIR-II emission was continuously registered during the irradiation process by a fibre-coupled spectrometer.
  • Fig. 1 a depicts a high-angle annular dark-field imaging scanning transmission electron microscopy (HAADF-STEM) image of the as-synthesized Ag S dots. They present an elliptical shape with an average size of 9.5 ⁇ 1.0 nm (see Fig. 10). Two well-differentiated regions can be distinguished: a high electrodense core located eccentrically and a less electrodense area that constitutes the major part of the NP.
  • the less electrodense area in Fig. 11 b is postulated to be Ag2S, as the density of Ag2S (7.2 g/cm 3 ) is lower than that of Ag (10.505 g/cm 3 ).
  • This assumption is corroborated by the energy dispersive X- ray spectroscopy (EDS) analysis shown in Fig. 11c, d and e.
  • EDS energy dispersive X- ray spectroscopy
  • Fig. 11 g The anisotropic distribution of elements is depicted in the net X-ray intensity profiles shown in Fig. 11 g as obtained from the magnified STEM micrograph shown in Fig.11f.
  • Fig. 11g we can observe that the maximum of the X-ray intensity assigned to the Ag atoms arises from the electrodense region, while the X-ray intensity signal attributed to the S atoms becomes maximum in the less electrodense area.
  • the elemental analysis of a Ag2S dot shows a Ag:S ratio of 74:26. All these results support the presence of a metallic
  • FIG. 12 and 13 include X-ray diffraction (XRD) patterns, X-ray absorption near edge structure (XANES) spectra, energy-dispersive X-ray (EDS) spectra and High-angle annular dark-field scanning transmission electron microscopy (HAADF-STEM) images of the Ag S dots and superdots.
  • XRD X-ray diffraction
  • XANES X-ray absorption near edge structure
  • EDS energy-dispersive X-ray
  • HAADF-STEM High-angle annular dark-field scanning transmission electron microscopy
  • nanoparticles when these nanoparticles are irradiated with an ultrafast laser, the chemical composition and structure of the nanoparticles changes and the resulting nanoparticles exhibit a new AgCI phase that would cover the nanoparticles forming a thin shell as observed in Fig. 11 i.
  • Fig. 14a shows the optical image of a colloidal dispersion of as Ag S dots in CHC before and after ultrafast laser irradiation (50 fs, 90 min, 9 W/cm 2 ) that, as explained in the previous section, leads to the formation of a AgCI shell around the Ag S dots.
  • Ultrafast laser irradiation induces an evident colour change in the dispersion, which becomes progressively more transparent.
  • the absorption spectra of the dispersions before and after irradiation are shown in Fig. 14b.
  • NIR-II brightness enhancement also takes place progressively during ultrafast irradiation as observed in Fig. 14d., which shows the time evolution of the NIR-II emission of Ag S dots during ultrafast laser irradiation. Inset in Fig. 14d reveals that such NIR-II brightness enhancement is achieved without producing any relevant change in the spectral shape of the emission.
  • Fig. 14e shows the fluorescence quantum yield (QY) of different colloidal dispersions of Ag S dots in CHCh after ultrafast laser irradiation (50 fs, 9 W/cm 2 ) for different illumination times.
  • the QY increases monotonously with the irradiation time for treatment durations shorter than 40 min. Longer irradiations do not lead to any further improvement in the QY.
  • As-synthetized dots show a QY of 0.13% that increases up to 10.7 % after 50 min irradiation with 50 fs pulses.
  • Fig. 14e shows the fluorescence quantum yield (QY) of different colloidal dispersions of Ag S dots in CHCh after ultrafast laser irradiation (50 fs, 9 W/cm 2 ) for different illumination times.
  • the QY increases monotonously with the irradiation time for treatment durations shorter than 40 min. Longer irradiations do not lead to any further improvement in the QY.
  • FIG. 16 includes some representative excitation and emission spectra used for the calculations of the QY values included in Fig. 14e. This constitutes an 80-fold enhancement, validating our referring to the laser- irradiated Ag S dots as superdots.
  • This QY enhancement is accompanied by a substantial increase in the fluorescence lifetime from 200 ns up to 2.1 ps, as shown in Fig. 14f. This lifetime increase follows the same trend with the irradiation time observed for the QY in Fig. 14e and it is independent of the dot concentration in the 0.1-1 mg/mL range. This fact rules out the possible influence of fluorescence self-absorption in our lifetime measurements.
  • Fig. 17a shows the time evolution of the NIR-II fluorescence intensity generated by a colloidal dispersion of dots in CHCh during ultrafast laser irradiation at different irradiation power densities. Curves included in Fig. 17a are obtained while maintaining the pulse duration (50 fs), repetition rate (1 kHz), and average power (0.6 W) of the irradiation laser. For irradiation power densities below 3 W/cm 2 , which seems to be a threshold value, no apparent improvement in the luminescence properties is observed.
  • the NIR-II fluorescence intensity increases with the irradiation time.
  • E p irradiation pulse energy
  • irradiation power densities higher than 10 W/cm 2 lead to a decrease in the emitted intensity for long irradiation times that could be attributed to degradation of the sample. This effect is highlighted when the irradiation power density is close to 100 W/cm 2 . Under these conditions, an initial increase in the emission intensity is followed by an abrupt reduction, rendering a non-luminescent and completely transparent dispersion that indicates the complete degradation of the sample.
  • the fluorescence intensity of the irradiated solution is represented as a function of the irradiation power density, the existence of an optimum irradiation power density close to 9 W/cm 2 becomes evident (see Fig. 18).
  • Fig. 17d shows the time evolution of the NIR-II fluorescence intensity generated by a dispersion of Ag Sdots in CHCh during irradiation with laser pulses of 50, 100, 200 and 550 fs. All the curves included in this figure were obtained with the same irradiation power and irradiation power density (0.6 W and 9 W/cm 2 , respectively).
  • the efficiency of the dot-to-superdot transformation decreases as the pulse duration increases.
  • CW laser irradiation does not lead to any improvement in the NIR-II fluorescence, indicating the absence of any dot- to-superdot transformation.
  • the experimental evidence shown in the figures allows us to provide a plausible explanation for the dot-to-superdot transformation. This is schematically shown in Fig. 17e. Due to the synthesis route used here, the as-prepared dispersions of Ag Sdots also contain Ag NPs whose plasmon resonance is responsible for the extinction peak observed at around 400 nm.
  • the interaction of the laser generated AgCI molecules with the surface of the Ag S dots results in the formation of a AgCI protective shell (steps 3 and 4 in Fig. 17e). Therefore, after ultrafast laser irradiation, the low-bandgap semiconductor Ag S (0.9 eV) is coated with an inorganic shell of higher-bandgap AgCI (5.13 eV) several monolayers thick, as seen in Fig. 11 i.
  • This protective shell strongly reduces the non-radiative transitions that involve the vibronic activation of solvent CHCh molecules and prevents the formation of shallow or deep midgap states as surface traps that would provide non-radiative deexcitation pathways.
  • the Ag core does not show any plasmonic resonance in the visible domain due to the presence of Ag S surrounding it.
  • the spectral location of the plasmon resonance of Ag nanoparticles strongly depends on the dielectric constant/refractive index of the surrounding medium [https://doi.org/10.1021/ja300901e]
  • the very different dielectric constants/refractive indices of chloroform and Ag S could be behind this effect.
  • the Ag nanoparticles exhibit a plasmon resonance at 425 nm, which favours nonlinear multiphoton absorption.
  • Fig. 19a also includes, for the sake of comparison, the fluorescence decay curve obtained for commercially available (Sinano Corp. China) PEG-coated Ag2S dots also dispersed in PBS.
  • Fig. 19b shows the in vivo NIR-II fluorescence images obtained in each case for 808 nm illumination power densities ranging from 227 down to 0.3 mW/cm 2 .
  • the depth of a subcutaneous injection is not fully controllable even when following the exact same protocol. Nevertheless, the inhomogenous thickness of mouse skin ( ⁇ 80 mhi over 400 mhi) could lead to negligible variation in transmitted fluorescence when compared with the orders of magnitude experimentally observed (Fig 19c), which are caused by the superior brightness of Ag S superdots.
  • the superior NIR-II brightness of Ag S superdots enables the acquisition of reliable fluorescence images even at the ultra-low irradiation power density of 0.3 mW/cm 2 . This not only allows in vivo imaging with cost-effective excitation sources but also ensures a negligible thermal loading during image acquisition.
  • Fig. 19c shows the in vivo fluorescence images of an anesthetized mouse after intravenous injection of Ag S superdots as obtained for three representative 808 nm excitation densities. Images were acquired 30 min after injection, and the fluorescence images reveal accumulation of superdots at both liver and spleen.
  • Fig. 19d shows the in vivo fluorescence images of an anesthetized mouse after intravenous injection of Ag S superdots as obtained for three representative 808 nm excitation densities. Images were acquired 30 min after injection, and the fluorescence images reveal accumulation of superdots at both liver and spleen.
  • 19e shows the dependence of the signal-to-noise ratio (SNR, expressed in dB) of the in vivo images as a function of the excitation power density. A linear relation between the SNR and excitation power density is obtained. For an excitation power density as low as 10mW/cm 2 the SNR of the in vivo image is above
  • FIG. 19h includes the intensity profiles, obtained with both Ag2S dots and superdots, along the dashed lines included in the fluorescence images and that correspond to a cross section of a secondary vessel.
  • the presence of this secondary vessels is clearly evidenced by Ag2S superdots while they are impossible to observe when using Ag2S dots.
  • the analysis of the intensity profile of the secondary vessel obtained with Ag2S superdots reveal that they provide a sub-200 nm spatial resolution.
  • Fig. 20a shows the NIR-
  • the illumination power density here used is also much lower than the safety threshold at this wavelength (329 mW/cm 2 ) established by the International Commission on Non-ionizing Radiation Protection (ANSI Z136.1-2000).
  • NIR-II video recording enabled us to track the in vivo biodistribution of our Ag2S superdots.
  • the time evolution of the NIR-II fluorescence intensity generated by the Ag2S superdots at the liver, spleen, heart and femoral artery after intravenous injection is shown in Fig. 20b.
  • the PEG-coated superdots were mainly circulating and gathering in the liver, spleen and heart.
  • the fluorescence signal observed at the femoral artery is assigned to the presence of Ag2S superdots in the bloodstream.
  • This curve By fitting this curve to a first-order exponential, we can estimate that the blood half-life of our Ag2S superdots is close to 20 min.
  • Fig. 20a and 20b most of the Ag2S superdots have been uptaken by the liver and spleen after 30 minutes.
  • the presence of superdots in these organs was corroborated by ex vivo NIR-II images taken 100 minutes after injection (Fig. 20c).
  • the high accumulation rates of NPs in the liver and spleen, which has been widely reported is related to filtration mechanisms promoted by the reticuloendothelial system (RES).
  • RES reticuloendothelial system
  • Ethanol absolute, n-hexane (95%), Silver nitrate (99%), L-Cysteine (96%), sodium diethyldithiocarbamate (DDTC) (ACS reagent grade), CHCh (99.6%), HS-PEG-COOH (2100 g/mol), and PBS tablets were purchased from Sigma-Aldrich (Germany) and used as received.
  • a Ti:Sapphire amplified was used (Spitfire from Spectra- Physics) that was pumped by a Ti:Sapphire oscillator (Tsunami from Spectra-Physics) both operating at 808 nm wavelength.
  • the amplifier provides pulses with a repetition rate of 1 kHz and tunable pulse widths in the 50-550 femtosecond range by fine adjustement of the compensating gratings.
  • the irradiation average power was controlled by using a set of polarizers and a l/2 waveplate (AQWP10M-980 from Thorlabs).
  • a 45 cm focal length lens was used to focus the irradiation beam into a hermetically closed quartz cuvette containing the dispersion of Ag S dots in CHCh dispersion.
  • the Ag S concentration was set in all the irradiation experiments to 1 mg/ml_.
  • the focusing lens was mounted on a translation stage that allowed changing the lens-to-cuvette distance and, hence, the laser spot size in the solution. This, in turns, made possible to change the laser power density while keeping the average laser power constant.
  • the NIR-II emission was continuously registered during the irradiation process by a fibre-coupled spectrometer with enhanced sensitivity in the 900-1700 nm spectral range (Ocean Optics NIRQUEST212).
  • thermocouple placed into the solution.
  • the distance between the thermocouple and the laser focal spot was set to 2 mm in order to avoid direct heating of the thermocouple by the 808 nm laser beam.
  • the synthesis of the Ag-NP-free Ag S dots was carried out by thermal decomposition of the precursor silver diethyldithiocarbamate (AgDDTC).
  • AgDDTC silver diethyldithiocarbamate
  • the precursor was synthesized as follows: 0.025 mol of AgNCh were dissolved in 200 ml_ of bidistilled water produced from Milli-Q water. Later 0.025 mol of DDTC (diethyldithiocarbamate) were dissolved in 300 mL of bidistilled water and added to the above solution. The resulting yellow powder was filtered and dried at 60 in vacuum using a rotary evaporator. After that, 25 mg of AgDDTC was dispersed in 5 mL of 1-dodecanethiol and the mixture was stirred under vacuum for 30 minutes.
  • the solution was heated up to 200 °C for 1 hour. After this time, the solution was cooled down naturally. When the temperature of the mixture reached 25°C, 10 mL of ethanol was added and the solution was centrifuged at 10,000 rpm for 10 minutes. The supernatant was discarded and the precipitate collected in 10 mL of CHCL.
  • the Ag S superdots were transferred from CHCh to water by a ligand exchange reaction between the octadecylamine and HS-PEG- COOH (Mw of 2100 g/mol).
  • 2 mg of Ag S superdots dispersed in 1 mL of CHCL were mixed with 1 mg of HS-PEG-COOH and sonicated for 5 minutes to facilitate the ligand exchange.
  • the CHCL was gently evaporated until reaching a total volume of 500 pL.
  • 500 pL of absolute ethanol were added and the dispersion was sonicated for 5 minutes. This process was repeated 4 additional times in order to ensure the maximum removal of CHCL.
  • the Ag S superdots dispersed in 1 mL of absolute ethanol were then concentrated to a volume of 100 pL and transferred dropwise to 900 pL of PBS, prepared by dissolving a tablet in 100 mL of Milli-Q water.
  • the DLS and Z-potential measurements were performed using a Zetasizer Nano ZS instrument (Malvern Instruments, U.K.). The accumulation time was determined automatically for each sample. The sample concentration was adjusted to obtain 3000 cps. The acquired data was processed using the software provided by Malvern (Zetasizer software v7.03).
  • the absolute photoluminescence quantum yield (QY) was measured with a calibrated spectrofluorometer (Edinburgh Instruments, FLS920) equipped with an integrating sphere (Jobin-Yvon).
  • a Xe lamp was used as the excitation source, filtered with a longpass filter (610 nm) and a monochromator (wavelength: 808 nm, bandwidth: 20 nm) and the detector has been a liquid nitrogen cooled NIR photo-multiplier tube (Hamamatsu, R5509-72).
  • the QY was calculated by dividing the total number of emitted photons in the 900-1700 nm range by the total number of absorbed photons at 808 nm.
  • Luminescence decay curves were obtained by exciting the colloidal suspensions of Ag2S NCs by a OPO oscillator pumped by frequently doubled Nd:YAG laser (Lotis), which provides 8 ns pulses at a repetition rate of 10 Hz.
  • the fluorescence intensity was detected with a Peltier-cooled photomultiplier tube with enhanced sensitivity in the NIR- II (Hamamatsu R5509-73).
  • the contribution of scattered laser radiation was removed by using two bandpass filters (Thorlabs FEL850) and a high brightness monochromator (Andor Shamrock 320).
  • the time evolution of the fluorescence signal was recorded and averaged by a digital oscilloscope (Le Cray Waverunner 6000).
  • NIR-II in vivo images were obtained in a homemade NIR-II system.
  • a fiber-coupled diode laser operating at 808 nm was used as excitation source (LIM030-F200-DL808).
  • the illumination power density was controlled by adjusting the diode current.
  • the anesthetized mouse was placed on a homemade temperature controlled plate operating at 36 °C.
  • the NIR-II fluorescence image was acquired with a Peltier cooled InGaAs camera (Xenics Xeva 320) cooled down to -40 °C.
  • Two longpass filters Thine FEL850 were used to remove the background signal generated by the scattered laser radiation.
  • mice were shaven and subcutaneously injected with 100 pl_ of a 1.5 mg/ml_ NP (Ag S superdots, Ag S dots, LaFs:Nd 3+ or SWNTs) dispersion in PBS.
  • NP Ag S superdots, Ag S dots, LaFs:Nd 3+ or SWNTs
  • mice received a small incision in the neck skin to expose the right jugular vein.
  • a polyethylene tubing catheter was inserted 2 mm in the caudal direction to infuse 100 mI_ of solution containing 1.5 mg/ml_ PEG-coated Ag S superdots dispersed in PBS.
  • mice were euthanized by isoflurane overdose and organs (liver, spleen, heart and lungs) were collected to obtain ex-vivo NIR-II images.
  • mice Four additional mice were intraperitoneally injected with 300 mI_ of a 500 pg/mL solution of Ag2S superdots in PBS.
  • mice intraperitoneally injected with 300 mI_ of PBS were used as control group.
  • the animals were housed in two separated cages in a room (23 ⁇ 2°C) maintained on a 12/12 h light/dark cycle with free access to food and water.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Materials Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Composite Materials (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

In this invention, we have developed a novel methodology that permits a significant increment in the quantum yield of Ag2S dots. The process is partly based on the irradiation of chloroform-dispersed Ag2S/Ag heterodimers with femtosecond laser pulses that lead to the formation of a protective AgCI shell. This reduces the surface traps while minimizing dot-to-medium transfer via non-radiative events. The Ag2S superdots generated as a result of this process outperform all currently available NIR-II contrast agents, enabling whole body in vivo imaging at ultra-low excitation intensities.

Description

Aq?S nanoparticles and methods of production thereof.
TECHNICAL FIELD OF THE INVENTION
The present invention refers to the biomedical field, in particular to nanoparticles for use as imaging fluorescent agents for in vitro and in vivo applications.
BACKGROUND OF THE INVENTION
Semiconductor nanocrystals emerged almost two decades ago as a new generation of fluorescent contrast agents capable of overcoming the intrinsic limitations of traditional fluorescent biomarkers (dyes and fluorescent proteins). The initial demonstration of the ability of these nanocrystals to generate high-contrast images at the cellular level was a major milestone in biophotonics and promoted the research in the field for the following years. The optimization of their chemical stability, biocompatibility and brightness was the major focus of the subsequent investigation. That resulted in the development of core/shell architectures, which constituted the second generation of semiconductor nanocrystals. These produced unparalleled results as cellular imaging probes but failed to enable deep-tissue in vivo imaging due to the poor penetration and high scattering of visible light into tissues. This limitation was overcome by the development of a third generation of semiconductor nanocrystals, emitting in the second near infrared window (NIR-II, 1 ,000-1 ,700 nm). In this spectral range, both tissue absorption and scattering coefficients are reduced to a minimum, allowing high-contrast, high-resolution in vivo imaging at large (> 1 cm) tissue depths9. NIR-II fluorescent semiconductor nanocrystals have changed the game in preclinical fluorescence imaging, enabling previously unthinkable feats such as high-resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes. NIR-II emitting Ag S nanocrystals are free from heavy metal ions, unlike other nanoprobes operating in this spectral range, minimizing biocompatibility concerns and making them the most promising system among all currently reported NIR-II fluorophores. Their properties have been exploited for multiple applications, including subcutaneous and transcranial thermometry 16, in vivo heart imaging, [https://doi.org/10.1007/s12274-019-2280-4.], photoacoustic imaging, [https://doi.org/10.1021/acsnano.6b07866], theranostics [https://doi.org/10.1007/s12274-018-2210-x], tumour diagnosis and dynamic imaging of the cardiovascular system. To enhance the clinical potential of Ag S dots, their properties need to be substantially improved to enable deep-tissue imaging at irradiation intensities well below the established safety threshold. Clinical use of NIR-II fluorescence imaging requires the improvement in the fluorescent properties of currently available NIR-II probes in order to increase the maximum penetration depth of the obtained images. In particular, the translation of Ag S dots into clinics requires a substantial increase in their fluorescence brightness, which is limited by their low quantum yield (QY) and short fluorescence lifetimes. Chemically synthesized Ag S dots typically present absolute QYs below 1% and lifetimes below <180 ns 20. These features have been attributed to the presence of surface and structural defects and to the dot-solvent interactions that favour electronic deexcitation via non-radiative pathways. Furthermore, the high redox potential of silver ions and the high temperatures required for Ag S dot synthesis lead to the simultaneous formation of metallic silver nanoparticles (NPs) that could also reduce the overall brightness due to plasmon coupling events. Currently available chemical synthesis routes have failed to avoid these non-radiative channels in Ag S dots. Therefore, the design and development of alternative and successful approaches becomes essential.
In this invention, we have developed two novel methodologies that permits a significant increment in the quantum yield of Ag S dots. DESCRIPTION OF THE INVENTION
As shown in example 1 , the present invention demonstrates the crucial role of the synthetic conditions on the photoluminescence properties of Ag S nanoparticles. More in detail, the effect of the solvent ratio of DDT and OLA during the nanoparticle generation via thermal degradation using an Ag(DDTC) was evaluated. In total, six different solvent ratios were tested (XDDT of 0.00, 0.15, 0.30, 0.60, 0.90 and 1.00). From a structural point of view, a clear decrease in nanoparticle size with an increase of DDT was observed, assumingly correlated to a more pronounced stabilization of small nanoparticles by the thiol bearing solvent DDT. Regarding the photoluminescent properties, a maximum of luminescence lifetimes and QY were observed for nanoparticles generated with a xDDT of 0.60. Measured luminescence lifetimes reached values of 1200 ns in comparison to lifetimes of 120 and 180 ns for the nanoparticles synthesized using xDDT of 0.00 and 1.00, respectively. For the QY, a 10-fold higher value of 2.3 % was determined for the nanoparticles synthesized with xDDT of 0.60 compared to the nanoparticles derived from neat solvents. As studied by EDS-mapping of the generated nanoparticles using xDDT of 0.00, 0.60 and 1.00, we were able to clearly correlate the improved photoluminescent properties to a more precise ratio of Ag and S in the final nanoparticle matrix. In addition, the surface modification of the Ag S nanoparticles allows for a transfer into aqueous solution. In this media our fabricated Ag S nanoparticles conserve the superb optical properties, exhibiting higher luminescence lifetimes and QY compared to commercially available PEGylated Ag S in aqueous buffer. This permits their usage as contrast imaging agents, where the nanoparticles present an excellent biodistribution.
Therefore, a first aspect of the invention refers to a method for manufacturing, preferably hydrophobic, Ag S nanoparticles comprising the following steps:
a. Mixing a given amount of silver such as for example in the form of Ag(DDTC) (silver diethyldithiocarbamate), preferably in an amount of about 25 mg (0.1 mmol), preferably at room temperature, with a solvent comprising a mixture based on an i) organic long-chain molecule, comprising between 4 and 20 carbon atoms in length and comprising an amine group, and ii) DDT (1-dodecanethiol) or any other thiol based molecule with a boiling point of less than 350°C, preferably less than 200°C, preferably between 140 and 200°C, such us 1- decanethiol, 1-undecanethiol, 1-penthadecanethiol, wherein the solvent mole fraction (xDDT) calculated as xDDT= (nDDT/(nDDT + organic long-chain molecule (such as nOLA) is between 0.30 and 0.90;
b. submitting the reaction mixture of a) to a temperature between 80°C and 350°C in, preferably a closed atmosphere; and
c. collecting the nanoparticles.
In a preferred embodiment, the solvent mole fraction (xDDT) is between 0.45 and 0.75. More preferably, the solvent mole fraction (xDDT) is between 0.55 and 0.65. More preferably, the solvent mole fraction (xDDT) is between 0.58 and 0.62. Still more preferably, the solvent mole fraction (xDDT) is between 0.59 and 0.61. Still more preferably, the solvent mole fraction (xDDT) is between 0.595 and 0.605. Still more preferably, the solvent mole fraction (xDDT) is between 0.598 and 0.602. Still more preferably, the solvent mole fraction (xDDT) is between 0.599 and 0.601- Still more preferably, the solvent mole fraction (xDDT) is about 0.60. Still more preferably, the solvent mole fraction (xDDT) is 0.60.
In another preferred embodiment of the first aspect of the invention, silver can be provided in any form such as those selected from the list consisting of: Ag(DDTC), silver nitrate, silver dihydrocarbyl thiophosphate, silver dioctyl sulfosuccinate, silver thiobenzoate, silver acetate, silver dodecanoate, silver tetradecanoate and silver octadecenoate.
In another preferred embodiment of the first aspect of the invention, the organic long- chain molecules are selected from the list consisting of octylamine, trioctylamine, dodecylamine, octadecylamine, and OLA (oleylamine). Preferably, such molecule is and OLA (oleylamine).
In another preferred embodiment of the first aspect of the invention or of any of its preferred embodiments, the closed atmosphere is created by using a vacuum, preferably for about 10 min, to remove air and then filled with N , other inert gases like Argon, or He can be also used.
In another preferred embodiment of the first aspect of the invention or of any of its preferred embodiments, in step b) the mixture is heated to a temperature between 120°C and 350°C, preferably between 150°C and 230°C, more preferably between 170°C and 210°C, still more preferably to a temperature about 190°C, under magnetic stirring, preferably with a heating rate of 20°C/min and under slow magnetic stirring.
In another preferred embodiment of the first aspect of the invention or of any of its preferred embodiments, prior to step c) the reaction is cooled down by any suitable means, preferably by naturally cooling the reaction.
In another preferred embodiment of the first aspect of the invention or of any of its preferred embodiments, in step c) the nanoparticles are preferably collected by the addition of ethanol, which reduces the colloidal stability of the nanoparticles, preferably by adding about 10 mL of ethanol to the raw product and centrifuging at about 10,000 rpm for 10 min, and preferably repeating this process twice.
In another preferred embodiment of the first aspect of the invention or of any of its preferred embodiments, the resultant product of step c) is dispersed in chloroform and stored.
A second aspect of the invention refers to a method for manufacturing pegylated hydrophobic Ag S nanoparticles comprising the following steps:
a. adding a hydrophilic agent such as 11-mercaptoundecanoic acid (MUA), dihydrolipoic acid, 2,3 dimercaptosuccinic acid, mercaptopropionic acid, or cysteine, to a dispersion containing Ag S/Ag nanoparticles as obtained from the method of the first aspect of the invention, preferably in chloroform at room temperature; b. Precipitating and collecting the product of step d);
c. Covering the precipitates of step e) with PEG, preferably PEG-NH2, more preferably via EDC/NHS coupling; and
d. Collecting the nanoparticles.
In a preferred embodiment of the second aspect of the invention, the precipitating step e) is performed by sonicating the mixture in an ultrasonic bath, preferably for 10 minutes, until the Ag2S/Ag nanoparticles lose their colloidal stability and precipitate.
In another preferred embodiment of the second aspect of the invention or of any of its preferred embodiments, the treatment with PEG via EDC/NHS coupling, in performed by dissolving EDC and sulfo-NHS in a saline solution such as PBS comprising the nanoparticles obtained from step e) and PEG.
A third aspect of the invention refers to, the preferably hydrophobic, Ag2S nanoparticles obtained or obtainable by the method of the first aspect of the invention or of any of its preferred embodiments.
A fourth aspect of the invention refers to pegylated Ag2S nanoparticles obtained or obtainable by the method of the second aspect of the invention or of any of its preferred embodiments.
A fifth aspect of the invention refers to a composition comprising the hydrophobic Ag2S nanoparticles of the third aspect of the invention.
A sixth aspect of the invention refers to a composition comprising the pegylated hydrophobic Ag2S nanoparticles of the fourth aspect of the invention.
A seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use as an in vivo imagining agent, or for in vivo fluorescence imaging, enabling features such as high-resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes.
A further application of the seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use in vivo diagnosis.
A further application of the seventh aspect of the invention refers to the composition of any of the fifth or sixth aspects of the invention or to the nanoparticles of the third or fourth aspects of the invention for use in in vitro diagnosis as a imagining agent, in particular as a fluorescence imaging agent.
A second part of the present invention, is shown in example 2, which demonstrates the potential of femtosecond laser pulses to radically improve the properties of luminescent nanostructures operating in the second biological window. The capacity of ultrafast laser irradiation to tune the structural and optical properties of infrared luminescent Ag S NPs shown here can undoubtedly expand their range of applications, especially in the field of nanomedicine. The advantages offered by these nanoparticles, as demonstrated here, including their photochemical stability, optimum spectral operation range and the 80-fold improvement in their quantum yield, constitute a large step towards their translation into the clinics. Our discovery, the ability of ultrafast laser pulses to improve the luminescent properties of nanoparticles, also stimulates new synthesis procedures that could benefit from the synergy between traditional chemical procedures and light-matter interaction processes.
Therefore, a second part of the present invention relates to hydrophobic Ag S nanoparticles capable of emitting in the near infrared with a quantum efficiency of 10% (representing a 50-fold increase with respect to the efficacy of the nanoparticles obtained so far) as well as to a method of synthesis of the same. Such nanoparticles can be superficially functionalized, making them especially suitable as imaging contrast agents in biological applications.
Therefore, an eight aspect of the invention refers to a method of manufacturing, preferably, hydrophobic Ag S nanoparticles comprising the following steps: a. Mixing a given amount of silver with a long chain organic molecule, preferably having between 4 and 20 carbons in length, comprising an amine group;
b. submitting the reaction mixed of a) to a temperature between 80°C and 350°C in, preferably a closed atmosphere; and
c. collecting the nanoparticles.
In a preferred embodiment of the eight aspect of the invention, preferably prior to collecting the nanoparticles, after step b) and preferably after a passive cooling process, a polar organic solvent is added to the mixture, centrifuged and the obtained nanoparticles are washed giving rise to the hydrophobic nanoparticles that are collected in step c). In a preferred embodiment of the eight aspect of the invention, silver is provided by using one or more molecules selected from the list consisting of: silver nitrate, Ag(DDTC) (silver diethyldithiocarbamate), silver dihydrocarbyl thiophosphate, silver dioctyl sulfosuccinate, silver thiobenzoate, silver acetate, silver dodecanoate, silver tetradecanoate and silver octadecanoate.
In another preferred embodiment of the eight aspect of the invention, the organic long- chain molecules are selected from the list consisting of octylamine, trioctylamine, dodecylamine, octadecylamine, and OLA (oleylamine).
In a ninth aspect of the invention, the nanoparticles of the eight aspect of the invention, or the nanoparticles of the first or second aspects of the invention are treated with an ultra-fast laser treatment, wherein such treatment is performed by dispersing the Ag S nanoparticles in chloroform, dichloromethane, dichloroethane, trichloroethane or in any organic solvent comprising chlorine; and wherein such nanoparticles may be optionally further subjected to a ligand exchange reaction to generate hydrophilic Ag S nanoparticles. Preferably, the ion exchange reaction is carried out by mixing hydrophobic Ag S nanoparticles with an equivalent amount or an excess amount of a hydrophilic molecule comprising a thiol group so that the surface of the Ag S nanoparticles are functionalized by the hydrophilic group thus obtaining or resulting in hydrophilic particles. Preferably, the hydrophilic molecule is selected from the group consisting of: mercaptoacetic acid, mercaptopropionic acid, cysteine, cysteinamine, thioctic acid, ammonium mercaptoacetate, or any combination thereof. Preferably, the laser treatment is performed by dispersing the Ag S nanoparticles in chloroform.
In the context of the present invention, ultra-fast laser is understood as any laser capable of producing laser pulses with a temporal duration below 500 femtoseconds.
It is noted that the ion exchange ligand reaction of the ninth aspect of the invention can be carried out by mixing hydrophobic Ag S nanoparticles with an equivalent amount or an excess amount of a hydrophilic molecule that contains a thiol group, in an organic solvent such as ethanol, methanol, acetone, chloroform, dichloromethane, toluene, 1- methyl-2-pyrrolidone or any combination thereof, at a temperature between 0 and 80°C for a period of about 1 hour or more. The reaction time can be modified according to the reactivity and solubility of the stabilizing molecule. The pH of the aqueous solutions used during this reaction should be between 7 and 14. After the reaction has been carried-out, the nanoparticles are preferably washed with an aqueous solution to remove any residues. It is further noted that the ultra-fast laser shall be applied for a period of time that will depend on the specific characteristics of the laser, among which are: wavelength, pulse length, frequency, applied power density and beam diameter size. It is still further noted that the ultrafast laser treatment of the ninth aspect of the invention, induces a structural change that eliminates defects and increases the quantum efficiency of the nanoparticles. This process is preferably performed by dispersing the Ag S nanoparticles in chloroform, dichloromethane, dichloroethane, trichloroethane or any organic solvent containing chlorine.
In a preferred embodiment of the ninth aspect of the invention, the nanoparticles are irradiated using an ultra-fast laser at a wavelength, preferably between 200 and 1000 nm, more preferably between 300 and 900 nm, more preferably between 400 and 800 nm, still more preferably about 800 nm; with a power density of less than 40W/cm2, preferably between 3 and 30 W/cm2, more preferably between 6 and 10 W/cm2, still more preferably about 9 W/cm2; with pulses of less than 500 femto-seconds, preferably with pulses of about 50 femto-seconds; and at preferably a frequency of 1 kHz for preferably approximately 10 minutes.
As a result of the methodology shown in the ninth aspect of the invention, we have developed a novel methodology that permits a significant increment in the quantum yield of Ag S dots. The process is partly based on the irradiation of chloroform-dispersed Ag S/Ag heterodimers with femtosecond laser pulses that lead to the formation of a protective AgCI shell. This reduces the surface traps while minimizing dot-to-medium transfer via non-radiative events. The Ag S superdots generated as a result of this process outperform all currently available NIR-II contrast agents, enabling whole body in vivo imaging at ultra-low excitation intensities. The nanoparticles as obtained by the ninth aspect of the invention obtained have a quantum efficiency close to 10% and a high fluorescence, stability and excellent biocompatibility, so they can be used as contrast agents both in cellular image and in vivo imaging.
Therefore, a tenth aspect of the invention refers to Ag S nanoparticles obtained or obtainable by the method of the ninth aspect of the invention or of any of its preferred embodiments.
An eleventh aspect of the invention refers to a composition comprising the Ag S nanoparticles of the tenth aspect of the invention.
A twelft aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use as an in vivo imagining agent, or for in vivo fluorescence imaging, enabling features such as high- resolution anatomical imaging, brain vasculature mapping and even dynamic tracking of metabolic processes.
A further application of the twelfth aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use in vivo diagnosis.
A further application of the twelfth aspect of the invention refers to the composition of the eleventh aspect of the invention or to the nanoparticles of the tenth aspect of the invention for use in in vitro diagnosis as a imagining agent, in particular as a fluorescence imaging agent.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. HAADF-STEM micrograph of nanoparticles obtained under different synthetic conditions (from A1 to F1). The insets from A2 to F2 represent the EDS elemental mapping of silver while the insets from A3 to F3 depict the EDS elemental mapping of sulfur. From A4 to F4, merged figures resulting from the HAADF-STEM and EDS elemental analysis are showed. The insets from A5 to F5 show detailed magnifications of the merged EDS and HAADF-STEM micrographs.
Figure 2. XRD patterns of Ag S/Ag nanoparticles synthesized using different ratios between DDT/OLA, Ag2S-1.00 black, Ag2S-0.60 blue, Ag2S-0.15 pink, Ag2S-0.90 orange, Ag2S-0.30 green, Ag2S-0.00 cyan.
Figure 3. Mean size of the Ag S/Ag nanoparticles (green) and the Ag cores (red) as a function of the DDT/OLA ratio.
Figure 4. A) Normalized UV-Vis spectra of the nanoparticles synthesized under different solvents ratios. Inset A1 shows the absorbance change as a function of the wavelength. B) PL emission spectra of the samples. Insets B1 and B2 show the variation of the maximum of the emission wavelength and the maximum of the PL intensity as a function of the solvent ratio. C) PL decay curves of the different nanoparticles. D) Lifetimes and absolute quantum yields as a function of the solvent ratio. The color legend is as follows: Ag2S-0.00 cyan, Ag2S-0.15 red, Ag2S-0.30 green, Ag2S-0.60 blue, Ag2S-0.90 orange, Ag2S-1.00 black, with numeric values indicating the XDDT.
Figure 5. EDS-mapping profile of the Ag S/Ag nanoparticles (A, D and G. Net X-ray profile extracted from the yellow arrow marked in the STEM images (B, E, and H). Merged STEM and nanoparticles model images represented as a function of Ag/S ratio versus the probe position (B, E and H). Frequency distribution of the Ag/S ratio in the nanoparticles excluding the silver core (C, F and I). The nanoparticles used for EDS- mapping were derived using XDDT of 0.00 (A-B), 0.60 (D-F) and 1.00 (G-l) during synthesis.
Figure 6. A) Schematic representation for the surface modification of the nanoparticles by ligand exchange reaction with MUA and its subsequent PEGylation through EDC/sulfo-NHS coupling reaction. Graphic B) Evolution of the nanoparticle hydrodynamic diameter during the surface functionalization process. C) PL decay times of Ag S/Ag nanoparticles in CHC (green), Ag S/Ag-PEG nanoparticles in PBS (blue) and Ag S-PEG nanoparticles synthesized by Zhang’s method in PBS (red).
Figure 7. A) In vivo imaging of an anesthetized mouse 5 min after intravenous injection of the here optimized Ag2S nanoparticles. The animal was optically excited with an 800 nm laser diode and luminescence (1000-1400 nm) was recorded with an infrared camera. B) Magnification of the lower extremities where the femoral vessels can be observed. C) A cross-sectional intensity profile measured along the black dashed line in (B). D) ex vivo NIR-II image of dissected mouse of the skeleton E) lung spleen and liver and F) detailed image of femur, tibia, ilium, and sacrum of mice.
Figure 8. (a) TEM image of the as synthesized Ag2S/Ag nanoparticles (b) HR-TEM of a single electrodense nanoparticle, showing its polycrystalline structure with lattice fringe 0.20 and 0.23 nm. (c) HAADF-STEM image of the as synthesized Ag S/Ag nanoparticles
(d) EDS elemental analysis obtained from a high Z-contrast nanoparticle labelled with the red crosshair.
Figure 9. (a) STEM micrograph of AgCI NPs obtained by ultra-fast laser irradiation of the sample (b) and (c) 2D EDS mapping of the spatial distribution of Cl (b) and Ag (c) reveals that these NPs are basically constituted by AgCI. This result is further confirmed by EDS analysis in (d). (e) XRD analysis of the sample shows the typical reflection of cubic AgCI crystals.
Figure 10. (a) and (b) are HAADF-STEM image of Ag S dots and superdots, respectively (c) and (d) show the size distributions of Ag S dots and superdots, respectively. Orange and red bars correspond to size distribution of Ag core and whole NP, respectively (e) Schematic representation of the structure ofAg S dots. The average sizes of whole nanoparticle and Ag core are indicated (f) Schematic representation of the structure of Ag S superdots, including the sizes. The average sizes of whole nanoparticle and Ag core are indicated. Figure 11. Tuning structural and chemical properties through ultrafast laser irradiation (a) HAADF-STEM micrograph of the as-synthetized Ag2S dots (b) High-resolution STEM of as-synthetized dots showing lattice fringes d111 and d-104 of cubic Ag and monoclinic Ag2S respectively. 2D EDS mapping of the spatial distribution of (c) Ag, (d) S and (e) Ag+S. (f) Magnified STEM micrograph of two Ag2S dots (g) Net X-ray intensity profiles extracted from the green arrow marked in (f), note how the Ag/S ratio increases at the edges of the dots, which coincides with the electrodense area. The inset shows a model nanoparticle (h) HAADF-STEM micrograph of Ag2S dots after ultrafast laser irradiation with 50 fs laser pulses for 90 min and with a power density of 9 W/cm2. (i) High-resolution STEM of an ultrafast laser irradiated Ag2S dot showing lattice fringes d111 and d110 of cubic Ag and monoclinic Ag2S respectively. Note the presence of a shell marked with a blue bracket around the nanoparticle. 2D EDS mapping of the spatial distribution of (j) Ag, (k) S, (I) Cl and (m) Ag+S+CI of an ultrafast laser-irradiated Ag2S dot. (n) Magnified STEM micrograph of an ultrafast laser-irradiated Ag2S dot. (o) Net X-ray intensity profiles extracted from the green arrow marked in image (n), where we can observe the presence of Ag, S and Cl. The inset on the left shows a schematic representation of a Ag2S heterodimer after ultrafast laser irradiation.
Figure 12. (a) XRD pattern of the as synthesized Ag2S dots sample. The red lines represent typical reflections of monoclinic Ag2S phase, whilst green lines represent the reflection positions of cubic Ag. (b) XANES spectra of Ag2S dots (red) and Ag2S used as reference (blue) and Ag foil used as reference (black) (c) EDS spectrum of Ag2S dots (d) EDS elemental mapping of Ag2S, silver (yellow), sulphur (red), the inset in the bottom left is the resulting image after merging S+Ag and the inset in the bottom right is the HAADF-STEM image from which the EDS map was collected. The scale bar is 10 nm. Figure 13. (a) XRD pattern of Ag2S superdots (b) XANES spectra of Ag2S superdots (orange) and Ag2S used as reference (blue), AgCI used as reference (red) and Ag foil used as reference (black) (c) EDS spectrum of Ag2S superdots (d) EDS elemental mapping of Ag2S superdots, silver (yellow), sulphur (red) and chlorine (blue). The inset in the bottom right is the resulting image after merging the S, Ag and Cl HAADF-STEM images. The scale bar is 10 nm.
Figure. 14. Optical transformation of Ag2S dots into superdots (a) Optical images, (b) VIS-UV extinction spectra, and (c) NIR-II fluorescence images of a colloidal dispersion of Ag2S dots in CHC before and after ultrafast laser irradiation (50 fs, 90 min, 9 W/cm2). For the acquisition of NIR-II fluorescence images, the dispersions were optically excited with an 808 nm continuous wave laser diode (100 mW/cm2). (d) NIR-II emission spectra generated by a colloidal suspension of dots in CHCh during a 90-minute-long ultrafast laser irradiation. The inset shows the normalized emission spectra of the sample before and after the laser irradiation (e) Fluorescence quantum yield and (f) fluorescence lifetime of Ag S dots in CHCh after being subjected to ultrafast laser irradiations processes of different durations. Error bars correspond to the standard deviations as obtained by measuring and analysing up to 10 decay curves for each sample. In (e) and (f), squares and circular points refer to the experimental data and the red lines are guides for the eyes.
Figure 15. (a) VIS-NIR extinction spectra of colloidal dispersions of Ag S dots in CHCh after ultrafast laser irradiation for different times (b) Extinction coefficient at 400 nm as a function of the ultrafast laser irradiation time, obtained from the spectra shown in (a) (c) Extinction coefficient at 808 nm as a function of the ultrafast laser irradiation time, as obtained from (a) (d) Fluorescence decay curves of colloidal dispersions of Ag2S dots in CHCh after ultrafast laser irradiation for different times. In all cases, the dispersions were treated with an ultrafast laser with the same pulse width, power density (50 fs, 9 W/cm2).
Figure 16. Illustrative examples of the spectra used for the determination of the QY. Data correspond to dispersions of Ag S dots and superdots in CHCh and in PBS. The spectra of the excitation light (808 nm) is measured with and without sample. From the difference between these spectra, the number of absorbed photons is calculated in each case. The number of emitted photons generated by each sample is calculated from the emission spectra recorded in presence of the sample. Then, the QY is calculated by dividing the number of emitted photons by the number of absorbed photons. All the emission spectra are corrected by the system response.
Figure 17. Required conditions and mechanisms of laser induced dot-to-superdot transformation (a) Time evolution of the NIR-II fluorescence generated by colloidal dispersions of Ag S dots in CHCI3 under irradiation at different power densities. In all cases, the pulse width and repetition rate were set to 50 fs and 1 kHz, respectively (b) Time evolution of the NIR-II fluorescence generated by Ag S dots dispersed in different solvents under laser irradiation with 50 fs, 808 nm laser pulses (c) Time evolution of the NIR-II fluorescence generated by Ag S dots under laser irradiation with 50 fs, 808 nm laser pulses in presence and absence of Ag NPs. (d) Time evolution of the NIR-II fluorescence intensity generated by Ag S dots in CHCh as obtained for different pulse durations. For all cases in (b), (c), and (d), the ultrafast laser power density was set to 9 W/cm2. (e) Schematic representation of the physicochemical mechanisms underlying the ultrafast laser-induced dot-to-superdot transformation. Upon illumination with ultrafast infrared laser pulses, multi-photon excitation of Ag NPs leads to their coulomb explosion (step 1). The Ag atoms generated in this process react with CHCh molecules forming AgCI (step 2), which in turn reacts with the surface of the Ag2S dots forming a protective layer (steps 3 and 4).
Figure 18. (a) Optical images and (b) NIR-II emission intensity for a dispersion of Ag2S in CHCh after a 100-minute-long ultrafast laser irradiation at different power densities. Figure 19. In vivo brightness of Ag2S superdots: a comparison with their competitors (a) NIR-II fluorescence decay curves of PEG-coated Ag2S dots (provided by Sinano Corp., China) and Ag2S superdots, both dispersed in PBS. (b) NIR-II fluorescence images of a group of mice subcutaneously injected with colloidal aqueous dispersions containing Ag2S superdots, commercial Ag2S dots, SWNTs and Nd-doped NPs. The same NP concentration was injected in all cases. The different images for same optical probe correspond to different 808 nm illumination power densities (c) The signal-to- noise ratio (SNR) as a function of power density quantified from the analysis of images in (b) as obtained for the four NIR-II nanoprobes evaluated. Note that Ag2S superdots enable the use of illumination power densities almost two orders of magnitude below those required for imaging with other NIR-II probes (d) Fluorescence images of Ag2S superdots accumulated in the liver obtained at three different excitation power densities with an 808 nm laser (200, 140, and 10 mW/cm2 from left to right) (e) Power density dependence of SNR calculated from the in vivo NIR-II fluorescence at different excitation power densities (10-200 mW/cm2). (f) and (g) NIR-II fluorescence images of the left leg of CD1 mice obtained 15 seconds after injection of 100 mI_ of Ag2S superdots and Ag2S dots, respectively. Concentration of the solution injected was 0.15 mg/ml_. (h) Cross- section intensity profiles of Ag2S superdots and Ag2S dots obtained along the dashed line depicted in (f) and (g) that corresponds to a secondary vessel. Dots are experimental data obtained from fluorescence images and solid line is the best fit to a Gaussian function from which the spatial resolution of the fluorescence image is estimated. Note that when using Ag2S dots their lower brightness do not allow the vissulaization of this secondary vessel.
Figure 20. In vivo time-resolved imaging with Ag2S superdots (a) NIR-II fluorescence images as obtained at different times after intravenous injection of 100 pi of a dispersion of Ag2S superdots in PBS at a concentration of 0.15 mg/ml_. (b) In vivo biodistribution of Ag2S superdots: time course of the fluorescence emission intensity at the liver, spleen, heart and femoral artery (c) NIR-II ex vivo fluorescence and optical images of the liver, spleen, heart and lungs. The mouse was euthanized 100 min after intravenous injection of Ag2S superdots (d) Time evolution of daily food intake (e) weight and (f) body temperature of CD1 mice after intravenous injection of 300 pL of a dispersion of Ag2S superdots in PBS (0.5 mg/mL, leading to a total dose of 150 pg of Ag2S superdots). The results obtained from a control group, which was intravenously injected with 300 pL of PBS, are included for comparison (g)-(i) Serum concentration of hepatic enzymes for mice intravenously injected with Ag2S superdots and for control mice as obtained 1 and 28 days after injection (j)-(k) Serum concentration of creatinine and bilirubin corresponding to mice subjected to an intravenous injection of Ag2S superdots and for control mice as obtained 1 and 28 days after injection. (n= 3 for each group). Error bars corresponding to standard error of the mean ± SEM.
Examples Example 1.
Experimental Section
1.1. Chemicals
Silver nitrate (99%), sodium diethyldithiocarbamate (NaDDTC) (ACS reagent grade), oleylamine (70%) (OLA), 1-dodecanethiol (<98%) (DDT), 11-mercaptoundecanoic acid (95%) (MUA), CHCIs (99,6%), ethanol (99.9%), A/-(3-(dimethylamino)propyl)-A/'- ethylcarbodiimide hydrochloride (EDC) (99%), /V-hydroxysulfosuccinimide sodium salt (Sulfo-NHS) (98%), 0-(2-aminoethyl)-0'-methyl- polyethylene glycol (PEG-NH2, Mp = 5.000 g/mol), and PBS tablets were purchased from Sigma-Aldrich and used as received. Commercial Ag2S-PEG nanoparticles were bought from NIR Optics technology.
1.2. Characterization
Transmission electron microscopy (TEM) studies were carried out using a TEM Talos F200X operated at 80 kV. Zeta-potential experiments were carried out using a Malvern Nano-ZS. The FTIR spectra were obtained using a Nicolet IR200 FTIR spectrometer. X- ray diffraction patterns were recorded on a Philips Xpert diffractometer (Cu-Ka radiation, 45 kV, 40 mA). Data were collected from 2Q = 20-90° with a step size of 0.02° and a normalized count time of 1 s/step. The emission spectra upon illuminating the samples with an 800 nm CW laser were collected with an Andor iDus InGaAs 491 cooled to -90°C. The absolute photoluminescence QY was measured with a calibrated spectrofluorometer (Edinburgh Instruments, FLS920) equipped with an integrating sphere (Jobin-Yvon). A Xe lamp has been used as excitation source, filtered with a long- pass filter (610 nm) and a monochromator (wavelength: 800 nm, bandwidth: 20 nm). Luminescence was detected by a liquid nitrogen cooled NIR photo-multiplier tube (Hamamatsu, R5509-72). The QY has been calculated by dividing the total number of emitted photons in the 900-1700 nm range by the total number of absorbed photons at 800 nm. Luminescence decay curves were obtained by exciting the colloidal suspensions of nanoparticles by an OPO oscillator (Lotis) tuned to 800 nm, which provides 8 ns pulses at a repetition rate of 10 Hz. Fluorescence intensity was detected with a Peltier cooled photomultiplier tube with enhanced sensitivity in the NIR-II (Hamamatsu R5509-73). The contribution of scattered laser radiation was removed by using two band-pass filters (FEL850 from Thorlabs) as well as a high brightness monochromator (Shamrock 320 from Andor). The time evolution of the fluorescence signal was finally recorded and averaged by a digital oscilloscope (LeCroyWaverunner 6000).
High-angle annular dark field (HAADF) scanning TEM and EDX mappings were conducted by using a FEI Talos F200X (FEI, USA) coupled to a EDX detector. Samples for TEM were prepared by adding 10 m\- of each dispersion on a Cu grid with a carbon support membrane, followed by drying.
1.3. in vivo imaging
NIR-II in vivo images were obtained in a homemade NIR-II system. A fiber-coupled diode laser operating at 800 nm was used as excitation source (LIM030-F200-DL808). The illumination intensity was controlled via adjustment of diode current. An anesthetized mouse was placed on a homemade temperature-controlled plate operating at 36 °C. The NIR-II fluorescence image was acquired with a Peltier cooled InGaAs camera (Xeva 320 from Xenics). The InGaAs detector was cooled down to -40 °C. Two long-pass filters (FEL850 from Thorlabs) were used to remove the background signal generated by the scattered laser radiation.
in vivo experiments were approved by the regional authority for animal experimentation of Comunidad de Madrid and were conducted in agreement with the Universidad Autonoma de Madrid (UAM) Ethics Committee, in compliance with the European Union directives 63/2010UE and Spanish regulation RD 53/2013. For this study, a total of 15 CD1 female mice (8-14 weeks old, weighing 25-39 g) bred at the animal facility at UAM were used. Mice were anesthetized prior to the imaging experiments in an induction chamber with a continuous flow of 4% isoflurane (Forane, AbbVie Spain, S.L.U) in 100% oxygen until loss of righting reflex was confirmed and breathing rhythm was significantly slowed. Anesthesia was maintained throughout the experiments by means of facemask inhalation of 1.5% isoflurane and core body temperature was kept at 36 ± 1 °C, as measured with a rectal probe, using a heating pad.
1.4. Synthesis of the Ag2S/Ag-PEG nanoparticles
The synthesis of the Ag2S/Ag-PEG nanoparticles was carried out in different steps as explained below. 1.4.1. Synthesis of Ag2S/Ag nanoparticles
The production of theAg2S/Ag nanoparticles was carried out as follows: a given amount of Ag(DDTC) typically 25 g (0.1 mmol) was added into a two-necked round bottom flask at room temperature, which contained 5 ml_ of a solvent mixture based on OLA and DDT. Table 1 shows the solvent mole fraction (XDDT) used in each synthesis, where XDDT= (nDDT/(nDDT+ noLA))·
Table 1. Solvent mixtures used in each synthesis. In all the experiments the amount of precursor Ag(DDTC) was kept constant at 25 mg (0.1 mmol).
Figure imgf000018_0001
Once all the reagents were introduced within the flask, the mixture was submitted to vacuum for 10 min to remove air and then filled with N2. After that, the mixture was heated to 190°C under magnetic stirring with a heating rate of 20°C/min and under slow magnetic stirring. The reaction was kept for 1 hour and subsequently cooled down naturally. The synthesized nanoparticles were collected by addition of ethanol, which reduces the colloidal stability of the nanoparticles. To do that, 10 L of ethanol were added to the raw product and centrifuged at 10,000 rpm for 10 min, this process was repeated twice. Finally, the as-prepared product was dispersed in 10 mL of chloroform and stored for further steps.
1.4.2. PEGylation of Ag2S/Ag heterodimers
With the aim of providing hydrophilicity to the synthesized nanoparticles, they were treated with MUA. This molecule can displace the hydrophobic ligands on the nanoparticles’ surface and introduce carboxylic groups on the surface of the nanoparticles, thereby providing good colloidal stability in water. With that purpose, 20 mg (0.1 mmol) of MUA was added to a 1 mL dispersion containing 1 mg/mL of Ag2S/Ag nanoparticles in chloroform at room temperature. After that, the mixture was sonicated in an ultrasonic bath for 10 minutes until the Ag2S/Ag nanoparticles lost their colloidal stability and precipitated at the bottom of the flask. Then, the precipitate was collected and dispersed in 1 mL of PBS at pH 7.4. Subsequently, these nanoparticles were covered with PEG-NH2 (Mp = 5000 g/mol) via EDC/NHS coupling. To do that, 0.5 mg of EDC and 0.7 mg of sulfo-NHS were dissolved in 1 mL of PBS containing 1 mg of the previously prepared Ag2S/Ag presenting MUA ligands and 1 mg of PEG-NH2. The mixture was gently stirred for 2 hours and after this time the nanoparticles were collected by centrifugation at 12.000 rpm for 2 hours. This process was repeated three times and the resulting nanoparticles were dispersed in 1 mL of PBS and stored at 4°C.
2. Results and discussion
Figure 1 depicts HAADF-STEM images of the Ag2S nanoparticles synthesized using different solvent ratios. As observed, all the nanoparticles exhibit two well-differentiated regions, a white area with higher Z-contrast, corresponding to the electrodense parts of the nanoparticles, probably due to the presence of metallic Ag into the nanoparticle. In addition, the figure shows the existence of less electrodense areas that appear as grey regions, corresponding to Ag2S.
The EDS elemental mappings showed in Figure 1 reveal the anisotropic spatial distribution of Ag (red) and S (green) within the nanoparticles. These micrographs unveil the presence of Ag enriched regions that overlap with those that exhibited higher Z- contrast (white regions in the HAADF-STEM). Interestingly, this silver core appears more eccentrically located when lower XDDT is used during the synthesis. XRD patterns of these nanoparticles reveal the presence of two crystalline phases, which could be attributed to monoclinic Ag S (JCPDS card No. 14-0072; lattice constants: a = 4.229 A, b = 6.931 A, c = 7.862 A) and cubic Ag (JCPDS card No. 04-0783; lattice constants: a = 4.0862 A), as seen in Figure 2. Interestingly, the synthetic conditions induce variations in the structure and properties of the synthesized nanoparticles. In fact, a decrease in overall nanoparticle size can be clearly correlated to an increase of XDDT during the reaction. Figure 3 shows the average size of each synthesis as well as the size of the electrodense region that corresponds to the silver core. This result can be explained in terms of the higher capacity of the DDT molecules to interact with the nanoparticles through the thiol group, which exhibits the highest binding energy towards noble metals (200 kJ/mol).34 Therefore, a high XDDT (high amount of DDT) leads to an increased colloidal stability of small nanoparticles formed during the course of the reaction and thus preventing the particles from aggregation resulting in a smaller overall nanoparticle size.
Figure 4 summarizes the impact of the synthetic conditions on the spectroscopic properties of the nanoparticles (absorption, photoluminescence, lifetime and QY). Figure 4A shows the normalized absorption spectra for all samples in the range between 300 to 900 nm. In all cases, a strong absorption in the visible region with weak shoulder at 465 nm and a long tail until the NIR region can be observed. The shoulder at -465 nm may be attributed to the plasmonic contribution of the metallic Ag present in the nanoparticle. It is important to note that this band only appears in those syntheses in which OLA is used. This indicates the role of the amino groups in the formation of metallic silver during the synthesis of the nanoparticles at high temperatures. In fact, it is well known that the synthesis of Ag S nanoparticles through the thermal decomposition of a silver precursor, like Ag-monothiobenzoate orAg-diethyldithiocarbamate, metallic Ag nanocrystals are formed as side products. This is because the dissociation energy of the Ag-S bond (206.45 kJ/mol) is lower compared to that of the S-C bond (265.95 kJ/mol) and, under a heating-up process, Ag ions are released in the absence of reactive sulfur. The addition of alkylamines in the reaction may lower the dissociation energy of the S-C bonds of the silver precursor via nucleophilic addition of an amine to the carbonyl group, thereby potentially providing a higher amount of reactive sulfur in the reaction resulting in an increased Ag S formation. Such an effect can be observed in Figure 2, here one can observe the reduction of the size of the Ag S matrix when increasing XDDT, whilst the size of the Ag core remains unchanged.
Figure 4B shows the emission band of the different samples as obtained under 800 nm optical excitation. The emission band is clearly affected by the synthesis conditions. Firstly, we observe that the peak wavelength is red-shifted when increasing XDDT. In fact, the nanoparticles synthesized only in the presence of OLA exhibit its maximum emission at 1160 nm, whilst those synthesized using only DDT as solvent showed its emission peak at 1220 nm. These variations indicate an increment in the bandgap of the nanoparticles when increasing the XDDT, which cannot be attributed to quantum confinement effects, since the size of all these nanoparticles are well above the Bohr radius of the Ag S. Another effect observed is a prominent variation of the luminescence emission intensity as a XDDT, which could be related to different emission efficiencies. For a better understanding, luminescence decay times of the nanoparticles were measured, see Figure 4C. From these results, we can observe an enhancement of the nanoparticle lifetimes from 120 ns to 1200 ns when increasing XDDT up to 0.60, see Figure 4D. Such an increment of the lifetimes is concomitant with the enhancement of the QY that increases from 0.2% to 2.3%. Surprisingly, a further increase of XDDT provoked a subsequent reduction of the lifetimes from 1200 ns to 180 ns as well as the QY values, from 2.4% down to 0.2%. For the lowest and the highest XDDT values, decreased PL lifetimes and QYs could be attributed to the increment of non-radiative pathways in the nanoparticles. All these results allowed us to identify the optimal synthetic conditions for the production of highly efficient Ag S nanoparticles.
In order to understand how synthetic conditions could affect the emission of the nanoparticles, we have analyzed the composition of the generated nanoparticles by EDS-mapping profile as seen in Figure 5. It is evidenced how the synthetic conditions affect tremendously the size, the shape, the position of the Ag enriched core and also the atomic ratio of Ag/S within the nanoparticles. In fact, the analysis of the Net X-ray profile of those nanoparticles synthesized with neat OLA (XDDT of 0.00, Figure 5A) allows to infer the Ag/S atomic ratio profile of such nanoparticles as seen in Figure 5B that is characterized by the presence of peaks that match with the position of the silver enriched region, while the rest of the regions present Ag/S atomic ratios around 2. When we represent the frequency distribution of the Ag/S ratio obtained in these nanoparticles, we can observe the presence of two Gaussian populations, one cantered at 1.8 and other at 2.2, which differs from a theoretical ratio of 2, which should correspond to a perfect Ag S matrix (Figure 5C). Such a result would indicate the presence of compositional inhomogeneities in the Ag S matrix that could render in structural defects. This fact would explain the low QY observed in this sample. Interestingly, those nanoparticles synthesized using a of 0.60 depict and Net X-ray profile different than the previous
Figure imgf000021_0001
nanoparticles, see Figure 5D. That informs us of Ag/S ratios very close to 2 for those areas distinct to the silver enriched regions, as seen in Figure 5G. When we represent the frequency distribution of the Ag/S ratio, we obtain a mean value centred at 1.9, which is closer to the hypothetical ratio of 2 the Ag2S matrix and would indicate the reduction of possible defects as shown in Figure 5F. That would be the reason why these nanoparticles exhibit an increment of the static emission as well as the PL lifetime and QY. Finally, in the case of those nanoparticles synthesized in the presence of neat DDT (Ύ DPT of 1.00), the Net X-ray profile shows the presence of a high concentration of silver, located preferentially in the core of the nanoparticles, Figure 5G. Such a profile creates a rapid increment of the Ag/S atomic ratio from a S enriched surface to a Ag enriched core, giving as a result a very small region where the matrix composition could be Ag2S, decreasing the NIR fluorescence of these nanoparticles, as shown in Figure 5H. On the contrary, the frequency distribution of the Ag/S ratio does not permit us to observe any maximum close to 2, which would indicate the presence of a thin Ag2S region surrounded by structural defects, which would render Ag2S nanoparticles with poor luminescent properties as observed in Figure 5I.
The optimized (from synthesis with XDDT of 0.60 with largest QY and luminescence lifetime) Ag2S nanoparticles were tested as NIR-II in vivo imaging contrast agents. To do that, ligand exchange reaction is carried out to substitute the hydrophobic capping agents by hydrophilic, thiol bearing molecules for their stabilization in aqueous media. Figure 6A shows the ligand exchange process. In the first step, carboxylic acid terminated MUA ligands are introduced on the nanoparticles’ surface, thereby acquiring negative charges which is confirmed by Zeta-potential measurements giving a value of ~ -27 mV. The hydrodynamic diameter of the MUA-functionalized nanoparticles is 14± 7 nm in PBS. After that, carboxylic groups were used as anchoring points, allowing for the linkage of PEG-NH2 molecules (5 kDa) through the amino terminated group, performing a coupling reaction mediated by EDO and sulfo-NHS. The products of this reaction are PEG- modified nanoparticles with a hydrodynamic diameter of 20 ± 9 nm and a Zeta-potential of -16 mV, which is still negative due to the presence of remaining carboxylate groups on the surface of the nanoparticles that did not react with PEG, as seen in Figure 6. After the ligand exchange reaction, the luminescence lifetime decreased as evident in Figure 6C, when these nanoparticles were coated with PEG and transfer to PBS, the lifetime suffered a reduction from 1200 ns down to 379 ns. The observed reduction of the lifetime can be associated to the environment assisted multiphoton relaxation processes, when the nanoparticles are dispersed in water, as it was previously observed.24 For the shake of comparison, we also measured the luminescence decay time of commercially available Ag2S-PEG nanoparticles in PBS (see Figure 6C). Note that our“optimized” Ag S nanoparticles showed a significantly increased luminescence decay time, revealing the effective reduction of non-radiative decays due to the improved Ag and S ratio in the final matrix. In order to demonstrate the potential of the“optimized” Ag S nanoparticles for in vivo imaging, 150 mI_ of a solution with a nanoparticle concentration of 1 mg/ml_ were injected in 1 -month-old CD1 female mice via retro-orbital injection. The anesthetized mouse was illuminated with a low power 808 nm laser diode providing an on-target laser power density as low as 45 mW/cm2. The luminescence generated by the Ag S nanoparticles was registered by an InGaAs infrared camera. In order to avoid any contribution of laser reflected light to the fluorescence image, a 1000 nm long-pass filter was used. In Figure 7A, an optical infrared fluorescence merged image of the mouse, as obtained 5 minutes after the injection of the nanoparticles, is shown. A clear luminescence signal is detected at the abdominal area of the mouse which is attributed to a fast accumulation of nanoparticles in the liver. Although the highest intensity is detected from the liver, a detailed inspection of the sub-abdominal region reveals also clear fluorescence contrast. The zoom included in Figure 7B reveals the presence of nanoparticles in the bloodstream. In particular, vessels of the lower limbs are evident in the amplified fluorescence image. Indeed, it is clear that, even by using this low excitation power density and low magnification optics, the optimized Ag2S nanoparticles are bright enough to provide an image of the vessel anatomy with a sub-millimeter spatial resolution (see intensity profile in Figure 7C). In order to elucidate the biodistribution of the injected nanoparticles, the animal were sacrificed 1 hour after injection and the presence of Ag2S in the different organs was elucidated from their fluorescence images. Figure 7D shows the fluorescence image corresponding to the skeleton, indicating the partial accumulation of Ag S nanoparticles within bones. Figure 7E includes the infrared fluorescence images corresponding to the liver, spleen, and lungs. Only these organs provided any relevant infrared fluorescence. This fact indicates that 1-hour post-injection the Ag S nanoparticles were accumulated at bones, lungs, liver, and spleen. Finally, Figure 7F shows an amplified fluorescence image of the bone structure of a limb. Note how the accumulation of Ag S nanoparticles at bones opens the way of obtaining high- resolution images of the skeleton by infrared fluorescence imaging. At this point we would like to stress that the accumulation of Ag S nanoparticles at bone structures could not only be used for advanced in vivo imaging of bone structure, but it can be also used for therapeutic effects. Note that Ag S nanoparticles, are also known to be excellent luminescent nanothermometers. This means that they could be potentially used to measure intra-bone temperature. This, in turns, becomes essential to achieve full control over photothermal therapies of bones, that have been recently demonstrated to be of high efficacy to promote bone regeneration.
Example 2. Preparation of Ag S dots and superdots.
Synthesis of AgåS dots. Ag/Ag S heterodimers (hereafter Ag S dots) were prepared as follows: 3 mmol of silver nitrate was poured into a round bottom flask containing 10 mL of octadecylamine at 160 °C under gentle stirring and N atmosphere. After 10 minutes, the mixture acquired a metallic blue color. At this stage, 1.5 mmol of L-cysteine was added to the mixture as sulphur source. As result, the colour of the mixture turned from blue to black indicating the formation of the heterodimer (30 minutes). Then, the sample was cooled down and the product of the reaction was dispersed in 40 mL of CHCI3. This dispersion was centrifuged at 21 ,000 g for 30 minutes and the precipitate was collected and dispersed in CHCI3 at a concentration of 1 mg/mL. The Ag S dots coexists with Ag nanoparticles that appear in the solution as side-products as demonstrated in Fig.8.
Ultrafast laser irradiation of AgåS dots. The above-described synthesis of Ag S dots yields silver nanoparticles (NPs) as a side product. The presence of these NPs is due to the high redox potential of silver ions under the reaction temperature. To eliminate them, a CHCI3 dispersion of the previously synthesized Ag2S dots at a concentration of 1 mg/mL was irradiated with a Ti:Sapphire femtosecond amplifier operating at 808 nm. Laser pulses trigger the transformation of Ag NPs into AgCI particles, which are unstable in the colloidal stability and easy to remove (see Fig. 9). The laser provides pulses with a repetition rate of 1 kHz and tunable pulse widths in the 50-550 femtosecond range. The real-time NIR-II emission was continuously registered during the irradiation process by a fibre-coupled spectrometer.
Physical characterization of AgåS dots before and after ultrafast laser irradiation.
Fig. 1 a depicts a high-angle annular dark-field imaging scanning transmission electron microscopy (HAADF-STEM) image of the as-synthesized Ag S dots. They present an elliptical shape with an average size of 9.5±1.0 nm (see Fig. 10). Two well-differentiated regions can be distinguished: a high electrodense core located eccentrically and a less electrodense area that constitutes the major part of the NP. The high-resolution STEM of a typical particle reveals a crystalline structure, as seen in Fig. 11 b, with lattice fringe dm = 2.30 A in the more electrodense part, in accordance with those of cubic Ag phase (JCPDS 04-0783). The less electrodense area exhibits a lattice fringe of d.io4 = 2.37 A that matches with the monoclinic Ag2S (JCPDS No. 14-0072). The less electrodense area in Fig. 11 b is postulated to be Ag2S, as the density of Ag2S (7.2 g/cm3) is lower than that of Ag (10.505 g/cm3). This assumption is corroborated by the energy dispersive X- ray spectroscopy (EDS) analysis shown in Fig. 11c, d and e. Here, we can observe that, while the NP core is rich in Ag, the S is mainly located in the outer part of the NPs. The anisotropic distribution of elements is depicted in the net X-ray intensity profiles shown in Fig. 11 g as obtained from the magnified STEM micrograph shown in Fig.11f. In Fig. 11g, we can observe that the maximum of the X-ray intensity assigned to the Ag atoms arises from the electrodense region, while the X-ray intensity signal attributed to the S atoms becomes maximum in the less electrodense area. The elemental analysis of a Ag2S dot shows a Ag:S ratio of 74:26. All these results support the presence of a metallic
Ag region within the Ag2S matrix.
After ultrafast illumination with 50 fs pulses for 90 min (9 W/cm2), the average diameter of the NPs increased from 9.5±1.0 nm to 12.3+1.0 nm, while the size of the metallic Ag core remained constant at around 5.1 nm, see Fig. 11 h. High-resolution STEM of a representative Ag2S dot after ultrafast laser irradiation (Fig. 11 i) reveals, again, two well differentiated crystalline regions, an electrodense one with lattice fringe of dm = 2.30 A, which agrees with metallic Ag, and a less electrodense area with a lattice fringe of duo = 2.50 A of the Ag2S. The presence of a 1-nm-thick shell around the NPs can also be observed in this figure. Based on the analysis of the corresponding crystal lattices, the conjunction interfaces between the metallic and the semiconductor part consist of the (110) plane of Ag2S and (111) of Ag, with a lattice mismatch of 8%. EDS images (Figs.11j-11 m) revealed that the resulting NPs are composed by Ag and S with an identical distribution as that observed in the as-synthesized NPs. Interestingly, EDS analysis detected the presence of Cl atoms distributed around the laser-irradiated Ag2S dots (Fig. 111). This stems from the formation of a AgCI shell. The presence of the AgCI shell is also evidenced in the net X-ray intensity profiles shown in Fig. 11o as obtained from the magnified STEM micrograph shown in Fig.11 n. The elemental analysis of a laser-treated Ag2S dot shows a Ag:S:CI ratio of 69:24:7. Again, the excess of Ag would indicate the conservation of the silver-rich core characteristic of the Ag2S dots. T o provide a complete chemical and structural characterization of the samples, figures 12 and 13 include X-ray diffraction (XRD) patterns, X-ray absorption near edge structure (XANES) spectra, energy-dispersive X-ray (EDS) spectra and High-angle annular dark-field scanning transmission electron microscopy (HAADF-STEM) images of the Ag S dots and superdots. These additional data support the conclusions extracted from Fig. 11 that the as-synthesized dots are composed of two phases, a monoclinic Ag S phase and a cubic Ag phase. Further, when these nanoparticles are irradiated with an ultrafast laser, the chemical composition and structure of the nanoparticles changes and the resulting nanoparticles exhibit a new AgCI phase that would cover the nanoparticles forming a thin shell as observed in Fig. 11 i.
Optical transformation of AgåS dots into superdots.
The structural changes induced in the Ag S dots by ultrafast laser pulses, summarized in Fig. 11 , are accompanied by a dramatic modification of their optical properties that is noticeable even by naked eye. Fig. 14a shows the optical image of a colloidal dispersion of as Ag S dots in CHC before and after ultrafast laser irradiation (50 fs, 90 min, 9 W/cm2) that, as explained in the previous section, leads to the formation of a AgCI shell around the Ag S dots. Ultrafast laser irradiation induces an evident colour change in the dispersion, which becomes progressively more transparent. The absorption spectra of the dispersions before and after irradiation are shown in Fig. 14b. This figure evidences that the irradiation with 50 fs laser pulses leads to a 35% decrease in the absorption coefficient in the 400-800 nm range. Data included in Fig. 15 reveal that this change takes place progressively during ultrafast laser irradiation. The absorption spectrum of the as-synthesized Ag S dots presents a shoulder around 400 nm, which is attributed to the plasmonic band of sub-100 nm Ag NPs and that is significantly reduced upon laser treatment. Besides modulating the absorption properties, ultrafast laser irradiation enhances the fluorescence brightness of the Ag S dots, as shown in the NIR-II fluorescence images in Fig. 14c, which correspond to a colloidal dispersion of dots before and after ultrafast laser irradiation (50 fs, 90 min, 9 W/cm2). The emission of the as-synthesized Ag S dots is barely detectable with our NIR-II imaging system, in contrast to the high brightness observed after the irradiation process. NIR-II brightness enhancement also takes place progressively during ultrafast irradiation as observed in Fig. 14d., which shows the time evolution of the NIR-II emission of Ag S dots during ultrafast laser irradiation. Inset in Fig. 14d reveals that such NIR-II brightness enhancement is achieved without producing any relevant change in the spectral shape of the emission. This result proves that the chemical nature of the fluorophore does not change upon irradiation. Fig. 14e shows the fluorescence quantum yield (QY) of different colloidal dispersions of Ag S dots in CHCh after ultrafast laser irradiation (50 fs, 9 W/cm2) for different illumination times. The QY increases monotonously with the irradiation time for treatment durations shorter than 40 min. Longer irradiations do not lead to any further improvement in the QY. As-synthetized dots show a QY of 0.13% that increases up to 10.7 % after 50 min irradiation with 50 fs pulses. Fig. 16 includes some representative excitation and emission spectra used for the calculations of the QY values included in Fig. 14e. This constitutes an 80-fold enhancement, validating our referring to the laser- irradiated Ag S dots as superdots. This QY enhancement is accompanied by a substantial increase in the fluorescence lifetime from 200 ns up to 2.1 ps, as shown in Fig. 14f. This lifetime increase follows the same trend with the irradiation time observed for the QY in Fig. 14e and it is independent of the dot concentration in the 0.1-1 mg/mL range. This fact rules out the possible influence of fluorescence self-absorption in our lifetime measurements.
Required conditions and mechanisms of dot-to-superdot transformation.
The ultrafast laser-induced dot-to-superdot transformation depends critically on multiple experimental variables. Fig. 17a shows the time evolution of the NIR-II fluorescence intensity generated by a colloidal dispersion of dots in CHCh during ultrafast laser irradiation at different irradiation power densities. Curves included in Fig. 17a are obtained while maintaining the pulse duration (50 fs), repetition rate (1 kHz), and average power (0.6 W) of the irradiation laser. For irradiation power densities below 3 W/cm2, which seems to be a threshold value, no apparent improvement in the luminescence properties is observed. For irradiation power densities between 3 W/cm2 and 8 W/cm2, the NIR-II fluorescence intensity increases with the irradiation time. In this range of power densities, the slope of the intensity vs time curve ( h = dl/dt ) depends strongly on the irradiation pulse energy (Ep). In fact, we find that h oc Ep , which suggests that the dot-to- superdot transformation is triggered by a two-photon absorption process. For irradiation power densities between 8 and 9 W/cm2 the NIR-II fluorescence intensity increases initially with irradiation time reaching a stable value for long irradiation times. Finally, irradiation power densities higher than 10 W/cm2 lead to a decrease in the emitted intensity for long irradiation times that could be attributed to degradation of the sample. This effect is highlighted when the irradiation power density is close to 100 W/cm2. Under these conditions, an initial increase in the emission intensity is followed by an abrupt reduction, rendering a non-luminescent and completely transparent dispersion that indicates the complete degradation of the sample. When the fluorescence intensity of the irradiated solution is represented as a function of the irradiation power density, the existence of an optimum irradiation power density close to 9 W/cm2 becomes evident (see Fig. 18). Fig. 17b demonstrates that ultrafast laser-induced dot-to-superdot transformation only occurs when the as-synthesized AgåS dots are dispersed in CHCU. When they are dispersed in water, toluene or hexane, pulsed irradiation leads to a decrease in their NIR-II fluorescence that can be attributed to laser-induced thermal loading. The presence of silver is also critical for the dot-to-superdot transformation. We corroborated this fact by analysing the effect of ultrafast laser irradiation in a Ag S dot sample free of Ag NPs. Ultrafast laser irradiation of these Ag S dots does not improve their fluorescence, as evidenced in Fig. 17c. Thus, we conclude that ultrafast laser driven dot-to-superdot transformation requires not only the presence of CHCh but also of Ag nanoparticles in the dispersion. Moreover, the dynamics of the dot-to-superdot transformation depends critically on the duration of the laser pulses. Fig. 17d shows the time evolution of the NIR-II fluorescence intensity generated by a dispersion of Ag Sdots in CHCh during irradiation with laser pulses of 50, 100, 200 and 550 fs. All the curves included in this figure were obtained with the same irradiation power and irradiation power density (0.6 W and 9 W/cm2, respectively). The efficiency of the dot-to-superdot transformation, estimated from the magnitude of the enhancement in the NIR-II emission, decreases as the pulse duration increases. In addition, CW laser irradiation does not lead to any improvement in the NIR-II fluorescence, indicating the absence of any dot- to-superdot transformation. The experimental evidence shown in the figures allows us to provide a plausible explanation for the dot-to-superdot transformation. This is schematically shown in Fig. 17e. Due to the synthesis route used here, the as-prepared dispersions of Ag Sdots also contain Ag NPs whose plasmon resonance is responsible for the extinction peak observed at around 400 nm. When excited by 808 nm ultrafast pulses, two-photon absorption by Ag NPs leads to the local induction of a high free electron density that results in their coulomb explosion (step 1 in Fig. 17e). The key role of multiphoton excitation is supported by the requirement of ultrafast laser pulses that ensure high photon densities and, hence, allows for sequential absorption through virtual states of Ag NPs. In addition, we have confirmed the participation of two 808 nm photons in the sequential process. The Coulomb explosion of Ag NPs leads to an increment in the concentration of highly reactive Ag atoms in the solution, which react with CHCh yielding silver chloride (AgCI): Ag+ +CI AgCI (step 2 in Fig. 17e). The interaction of the laser generated AgCI molecules with the surface of the Ag S dots results in the formation of a AgCI protective shell (steps 3 and 4 in Fig. 17e). Therefore, after ultrafast laser irradiation, the low-bandgap semiconductor Ag S (0.9 eV) is coated with an inorganic shell of higher-bandgap AgCI (5.13 eV) several monolayers thick, as seen in Fig. 11 i. This protective shell strongly reduces the non-radiative transitions that involve the vibronic activation of solvent CHCh molecules and prevents the formation of shallow or deep midgap states as surface traps that would provide non-radiative deexcitation pathways. The reduction in the non-radiative decay probabilities caused by this protective shell simultaneously explains the increment in the NIR-II QY and in the fluorescence lifetime. The decrease in the non-radiative decay probabilities is also evidenced by a reduction in the light-to-heat conversion efficiency when the dot-to- superdot transformation takes place. Both dots and superdots can be damaged under excessive irradiation doses, explaining why at high irradiation illumination power densities the initial enhancement in NIR-II luminescence is followed by a nonreversible quenching (see Fig. 17a). An arising question is why the multiphoton excitation and subsequent coulomb explosion takes place only in the colloidal Ag nanoparticles and not in the Ag cores. A plausible explanation is that the Ag core does not show any plasmonic resonance in the visible domain due to the presence of Ag S surrounding it. The spectral location of the plasmon resonance of Ag nanoparticles strongly depends on the dielectric constant/refractive index of the surrounding medium [https://doi.org/10.1021/ja300901e] The very different dielectric constants/refractive indices of chloroform and Ag S could be behind this effect. By contrast, the Ag nanoparticles exhibit a plasmon resonance at 425 nm, which favours nonlinear multiphoton absorption. That would render to an enhancement of the local electric field that in turn facilitates the electron stripping from the Ag nanoparticlesfacilitating the ionization of the Ag nanoparticles and the subsequent Coulomb explosion, in a similar way as it was described previously. [Chem. Phys. Lett. 229, 333 (1994)] In vivo NIR-II imaging with Ag2S superdots.
To test the potential application of Ag2S superdots for in vivo NIR-II imaging, we transferred them from their original solvent (CHCh) to phosphate buffer saline (PBS) by means of a ligand exchange procedure described in Methods. The adhesion of hydrophilic and bifunctional HS-PEG-COOH ligands on the surface of Ag2S superdots makes them stable in PBS without any sign of precipitation for at least 12 months. The average hydrodynamic diameter and Z-potential after the ligand exchange are 22 nm, and -25 mV, respectively. PEG coating and dispersion in PBS does not cause a significant reduction in the fluorescence decay time of Ag2S superdots, which is close to 2 ps (see Fig. 19a). The fact that Ag2S superdots show the same decay time in CHCh and in PBS reveals the effectiveness of the AgCI protective shell against the appearance of multiphonon relaxation events favoured by the vibration modes of water molecules. Hence, this makes it possible to retain the same QY « 10% in both solvents. Fig. 19a also includes, for the sake of comparison, the fluorescence decay curve obtained for commercially available (Sinano Corp. China) PEG-coated Ag2S dots also dispersed in PBS. The fluorescence lifetime of our PEG-coated Ag2S superdots dispersed in PBS is almost 40 times longer than that of commercial Ag2S dots in PBS (53 ns). Such a long fluorescence lifetime and high QY suggests the potential application of our PEGylated superdots for high-contrast, low-dose NIR-II in vivo imaging. To evaluate this possibility, we carried out a study to compare the performance of Ag2S superdots with that of other well-established NIR-II fluorescent probes: commercial Ag2S dots, neodymium-doped nanocrystals (LaFs:Nd3+) and single-walled carbon nanotubes (SWNTs). The FDA- approved ICG dye was not included in this comparative study as preliminary experiments revealed the poor spectral overlap between its emission tail and the spectral response of our NIR-II imaging system. We subcutaneously injected 100 mI_ of a PBS solution containing, in each case, Ag2S superdots, Ag2S dots, LaFs:Nd3+ and SWNTs into four different mice. The NP concentration was set in all cases to 1.5 mg/ml_, corresponding to a total injected NP dose of « 5 mg/kg. Fig. 19b shows the in vivo NIR-II fluorescence images obtained in each case for 808 nm illumination power densities ranging from 227 down to 0.3 mW/cm2. The superior performance of our Ag2S superdots is evident. These results support the fact that the Ag2S superdots synthesized in this invention show the highest NIR-II brightness among the NIR-II fluorescent probes evaluated here (see Table 2). Comparison of NIR-II brightness.
Figure imgf000031_0001
Table 2. Molar extinction coefficient at 800 nm, NIR-II fluorescence quantum yield (QY), NIR-II brightness and NIR-II fluorescence lifetime of the Ag S dots and superdots in both CHCh and PBS. The data for other well-established NIR-II fluorescent probes are also included.
At this point it should be noted that the depth of a subcutaneous injection is not fully controllable even when following the exact same protocol. Nevertheless, the inhomogenous thickness of mouse skin (±80 mhi over 400 mhi) could lead to negligible variation in transmitted fluorescence when compared with the orders of magnitude experimentally observed (Fig 19c), which are caused by the superior brightness of Ag S superdots. The superior NIR-II brightness of Ag S superdots enables the acquisition of reliable fluorescence images even at the ultra-low irradiation power density of 0.3 mW/cm2. This not only allows in vivo imaging with cost-effective excitation sources but also ensures a negligible thermal loading during image acquisition. At such ultra-low illumination power densities, no fluorescence from any of the other three tested NIR-II nanoprobes could be registered. The improvement in image contrast achieved by using Ag S superdots is quantified in Fig. 19c, which shows the power density dependence of the signal-to-noise ratio (SNR) calculated from the fluorescence images shown in Fig. 19b. From Fig. 19c, we conclude that the brightness improvement achieved during ultrafast laser irradiation reduces the minimum illumination density that can be used for in vivo imaging by almost two orders of magnitude. Such enhancement is also evident when comparing the illumination conditions used in this work to those reported in previous works dealing with Ag S dots, SWNTs and lanthanide-doped nanocrystals (see Table 3).
Table. 3. Reported experimental conditions for in vivo imaging with NIR-II nanoprobes.
Figure imgf000032_0001
Note that data included in Fig. 19c are obtained from the analysis of in vivo fluorescence images of subcutaneous injections. To provide an accurate and realistic number of the minimum power density that we can use for in vivo imaging, in vivo images obtained after intravenous injection of Ag S superdots are also analysed. Fig. 19d shows the in vivo fluorescence images of an anesthetized mouse after intravenous injection of Ag S superdots as obtained for three representative 808 nm excitation densities. Images were acquired 30 min after injection, and the fluorescence images reveal accumulation of superdots at both liver and spleen. Fig. 19e shows the dependence of the signal-to-noise ratio (SNR, expressed in dB) of the in vivo images as a function of the excitation power density. A linear relation between the SNR and excitation power density is obtained. For an excitation power density as low as 10mW/cm2 the SNR of the in vivo image is above
10 dB. Note that, according to Table 3, the acquisition of high contrast in vivo images with laser power densities of 10 mW/cm2 based on the use of Ag2S superdots constitutes and advantage over previous results using Ag2S dots for in vivo imaging. Table 3 reveals that previous works dealing with in vivo imaging by using Ag2S dots typically use power densities above 100 mW/cm2, i.e. one order of magnitude larger the power density used in this invention for in vivo imaging based on Ag2S superdots. The superior brightness of Ag2S superdots also allow for achieving larger penetration depths into tissues.
In addition, the potential use of our Ag2S superdots for in vivo visualization of vessels has been evaluated. Two CD1 female 3 month-old mice totally shaven were subjected to an intravenous tail injection with 100 mI_ of a 0.15 mg/ml_ dispersion of Ag2S dots and superdots in PBS respectively. 30 seconds after injection, magnified fluoresce images of the right limbs of both mice was acquired. Results are included in Figure 19f and 19g. Both images were obtained under the same experimental conditions (50 mW/cm2 808 nm excitation power density, emission signal filtered by two 850 nm and one 1100 long pass filters and a camera exposure time of 5 seconds). As it can be observed, Ag2S superdots enable blood vessel imaging with a much higher contrast than Ag2S dots thanks to their superior emission brightness. Such improvement allows not only better imaging of femoral artery but also to the visualization of additional vessels. Figure 19h includes the intensity profiles, obtained with both Ag2S dots and superdots, along the dashed lines included in the fluorescence images and that correspond to a cross section of a secondary vessel. The presence of this secondary vessels is clearly evidenced by Ag2S superdots while they are impossible to observe when using Ag2S dots. Indeed, the analysis of the intensity profile of the secondary vessel obtained with Ag2S superdots reveal that they provide a sub-200 nm spatial resolution.
The superior brightness of Ag2S superdots allows in vivo video rate NIR-II imaging at minimum illumination power densities and administered doses. Fig. 20a shows the NIR-
11 images obtained at different times after intravenous administration of 100 pl_ of PEG- coated Ag2S superdots dispersed in PBS at a concentration of 0.15 mg/ml_. This leads to a total dose of 15 pg, corresponding to approximately 0.5 mg/kg. This is more than one order of magnitude smaller than the administered dose (6.6 mg/kg) reported for NIR- II video recording using conventional Ag2S dots. The use of low administration doses for in vivo imaging is beneficial because of different reasons. Firstly, in order to develop a cost-effective probe for NIR-II in vivo imaging, it is mandatory to reduce the amount of material required to achieve high contrast in vivo images. Secondly, the use of low administration doses guarantees the minimization of possible adverse (toxicity) effects. Note that later in this work we demonstrate a negligible in vivo toxicity of our Ag2S superdots even for administration doses one order of magnitude larger than those required for in vivo imaging. Finally, Ag2S superdots shows a non-negligible photothermal conversion efficiency so that, in order to avoid undesirable heating during the acquisition of in vivo images the use of low administration doses and low illumination densities becomes mandatory. Images included in Fig. 20a were obtained by using an 808 nm illumination power density of 10 mW/cm2, one order of magnitude lower than the illumination power density employed for NIR-II video recording using SWNTs (140 mW/cm2)29. The illumination power density here used is also much lower than the safety threshold at this wavelength (329 mW/cm2) established by the International Commission on Non-ionizing Radiation Protection (ANSI Z136.1-2000). NIR-II video recording enabled us to track the in vivo biodistribution of our Ag2S superdots. The time evolution of the NIR-II fluorescence intensity generated by the Ag2S superdots at the liver, spleen, heart and femoral artery after intravenous injection is shown in Fig. 20b. For the first 3 min post-injection the PEG-coated superdots were mainly circulating and gathering in the liver, spleen and heart. The fluorescence signal observed at the femoral artery is assigned to the presence of Ag2S superdots in the bloodstream. By fitting this curve to a first-order exponential, we can estimate that the blood half-life of our Ag2S superdots is close to 20 min. As seen in Fig. 20a and 20b, most of the Ag2S superdots have been uptaken by the liver and spleen after 30 minutes. The presence of superdots in these organs was corroborated by ex vivo NIR-II images taken 100 minutes after injection (Fig. 20c). The high accumulation rates of NPs in the liver and spleen, which has been widely reported is related to filtration mechanisms promoted by the reticuloendothelial system (RES).
Finally, we evaluated the in vivo biocompatibility of our Ag2S superdots. We analyzed the time evolution of weight, daily food intake and temperature of a group of four CD1 mice after intravenous administration of 300 pl_ of a dispersion of Ag2S superdots in PBS at a concentration of 0.5 mg/ml_. This constitutes a total administration dose of 150 pg (5 mg/kg), one order of magnitude higherthan that used for NIR-II in vivo video recording. We compared the results obtained for mice injected with Ag2S superdots with those obtained for a control group of four mice, injected with 300 pl_ of PBS. Experimental data included in Fig. 20d-f reveal that, even for such relatively high administration doses, no differences are found when comparing the measured parameters for both groups. This suggests a negligible in vivo toxicity of our Ag S superdots. These findings are consistent with the reported low toxicity of conventional Ag S dots and with the already demonstrated ability of AgCI coatings to minimize NP cytotoxicity. Furthermore, to test the long-term biocompatibility of Ag S superdots we performed a 28 days subchronic toxicological experiment complemented with histological analyses regarding splenic, hepatic, and renal tissue samples. Materials and Methods of example 2.
Chemical Reagents.
Ethanol absolute, n-hexane (95%), Silver nitrate (99%), L-Cysteine (96%), sodium diethyldithiocarbamate (DDTC) (ACS reagent grade), CHCh (99.6%), HS-PEG-COOH (2100 g/mol), and PBS tablets were purchased from Sigma-Aldrich (Germany) and used as received.
Ultra fast laser irradiation.
For ultrafast laser irradiation, a Ti:Sapphire amplified was used (Spitfire from Spectra- Physics) that was pumped by a Ti:Sapphire oscillator (Tsunami from Spectra-Physics) both operating at 808 nm wavelength. The amplifier provides pulses with a repetition rate of 1 kHz and tunable pulse widths in the 50-550 femtosecond range by fine adjustement of the compensating gratings. The irradiation average power was controlled by using a set of polarizers and a l/2 waveplate (AQWP10M-980 from Thorlabs). A 45 cm focal length lens was used to focus the irradiation beam into a hermetically closed quartz cuvette containing the dispersion of Ag S dots in CHCh dispersion. The Ag S concentration was set in all the irradiation experiments to 1 mg/ml_. The focusing lens was mounted on a translation stage that allowed changing the lens-to-cuvette distance and, hence, the laser spot size in the solution. This, in turns, made possible to change the laser power density while keeping the average laser power constant. The NIR-II emission was continuously registered during the irradiation process by a fibre-coupled spectrometer with enhanced sensitivity in the 900-1700 nm spectral range (Ocean Optics NIRQUEST212). Real-time temperature measurements during irradiation were performed by means of a thermocouple placed into the solution. The distance between the thermocouple and the laser focal spot was set to 2 mm in order to avoid direct heating of the thermocouple by the 808 nm laser beam.
Synthesis and characterization of Ag-NP-free AgåS dots (neat AgåS dots).
The synthesis of the Ag-NP-free Ag S dots was carried out by thermal decomposition of the precursor silver diethyldithiocarbamate (AgDDTC). The precursor was synthesized as follows: 0.025 mol of AgNCh were dissolved in 200 ml_ of bidistilled water produced from Milli-Q water. Later 0.025 mol of DDTC (diethyldithiocarbamate) were dissolved in 300 mL of bidistilled water and added to the above solution. The resulting yellow powder was filtered and dried at 60 in vacuum using a rotary evaporator. After that, 25 mg of AgDDTC was dispersed in 5 mL of 1-dodecanethiol and the mixture was stirred under vacuum for 30 minutes. After that, the solution was heated up to 200 °C for 1 hour. After this time, the solution was cooled down naturally. When the temperature of the mixture reached 25°C, 10 mL of ethanol was added and the solution was centrifuged at 10,000 rpm for 10 minutes. The supernatant was discarded and the precipitate collected in 10 mL of CHCL.
Ligand exchange procedure.
In order to use the Ag S superdots for in vivo imaging, they were transferred from CHCh to water by a ligand exchange reaction between the octadecylamine and HS-PEG- COOH (Mw of 2100 g/mol). 2 mg of Ag S superdots dispersed in 1 mL of CHCL were mixed with 1 mg of HS-PEG-COOH and sonicated for 5 minutes to facilitate the ligand exchange. Afterwards, the CHCL was gently evaporated until reaching a total volume of 500 pL. Then, 500 pL of absolute ethanol were added and the dispersion was sonicated for 5 minutes. This process was repeated 4 additional times in order to ensure the maximum removal of CHCL. The Ag S superdots dispersed in 1 mL of absolute ethanol were then concentrated to a volume of 100 pL and transferred dropwise to 900 pL of PBS, prepared by dissolving a tablet in 100 mL of Milli-Q water.
Scanning transmission electron microscopy (STEM).
For the STEM studies a JEOL ARM200 cF was used. The microscope is equipped with a Cs corrector in the condenser lens and it is attached with an OXFORD INCA detector of 100 mm2 for XEDS analysis. The experiments were carried out at 80 KV as it was found that the sample were beam sensitive to higher acceleration voltages. Thus, and as a prior step, the stability was carefully checked in function of the different parameters of the microscope. In order to get the highest possible intensity in the XEDS detector without affecting the sample, we determined that the optimum conditions were achieved by using a condenser lens aperture of 50 micrometres and a spot size of 6. In these conditions, the probe current is well above 120 pA. The camera length for the STEM images was set to 6 cm so that the collection angles range is from 90 to 370 mrad.
Dynamic Light Scattering (DLS) and Z-potential determination.
The DLS and Z-potential measurements were performed using a Zetasizer Nano ZS instrument (Malvern Instruments, U.K.). The accumulation time was determined automatically for each sample. The sample concentration was adjusted to obtain 3000 cps. The acquired data was processed using the software provided by Malvern (Zetasizer software v7.03).
Quantum yield measurements.
The absolute photoluminescence quantum yield (QY) was measured with a calibrated spectrofluorometer (Edinburgh Instruments, FLS920) equipped with an integrating sphere (Jobin-Yvon). A Xe lamp was used as the excitation source, filtered with a longpass filter (610 nm) and a monochromator (wavelength: 808 nm, bandwidth: 20 nm) and the detector has been a liquid nitrogen cooled NIR photo-multiplier tube (Hamamatsu, R5509-72). The QY was calculated by dividing the total number of emitted photons in the 900-1700 nm range by the total number of absorbed photons at 808 nm.
Luminescence decay curves.
Luminescence decay curves were obtained by exciting the colloidal suspensions of Ag2S NCs by a OPO oscillator pumped by frequently doubled Nd:YAG laser (Lotis), which provides 8 ns pulses at a repetition rate of 10 Hz. The fluorescence intensity was detected with a Peltier-cooled photomultiplier tube with enhanced sensitivity in the NIR- II (Hamamatsu R5509-73). The contribution of scattered laser radiation was removed by using two bandpass filters (Thorlabs FEL850) and a high brightness monochromator (Andor Shamrock 320). The time evolution of the fluorescence signal was recorded and averaged by a digital oscilloscope (Le Cray Waverunner 6000).
In vivo imaging.
NIR-II in vivo images were obtained in a homemade NIR-II system. A fiber-coupled diode laser operating at 808 nm was used as excitation source (LIM030-F200-DL808). The illumination power density was controlled by adjusting the diode current. The anesthetized mouse was placed on a homemade temperature controlled plate operating at 36 °C. The NIR-II fluorescence image was acquired with a Peltier cooled InGaAs camera (Xenics Xeva 320) cooled down to -40 °C. Two longpass filters (Thorlabs FEL850) were used to remove the background signal generated by the scattered laser radiation. At this points we should note that in vivo images were also acquired using an additional 1100 nm long-pass filter, following previous works revealing that the use of such filter could increase the resolution of the NIR-II fluorescence image. In our case, the use of such filter does not leave to any significant increment in the image resolution.
In vivo experiments were approved by the regional authority for animal experimentation of Comunidad de Madrid and were conducted in agreement with the Universidad Autonoma de Madrid (UAM) Ethics Committee, in compliance with the European Union directives 63/2010UE and Spanish regulation RD 53/2013. For this study, 15 CD1 female mice (8-14 weeks old, weighing 25-39 g) bred at the animal facility at UAM were used. Mice were anesthetized prior to the imaging experiments in an induction chamber with a continuous flow of 4% isoflurane (Forane, AbbVie Spain, S.L.U) in 100% oxygen until loss of righting reflex was confirmed and breathing rhythm was significantly slowed. Anesthesia was maintained throughout the experiments by means of facemask inhalation of 1.5% isoflurane and core body temperature was kept at 36 ± 1 °C, as measured with a rectal probe, using a heating pad.
To study the imaging capabilities of the Ag S superdots compared to other NIR-II probes, four mice were shaven and subcutaneously injected with 100 pl_ of a 1.5 mg/ml_ NP (Ag S superdots, Ag S dots, LaFs:Nd3+ or SWNTs) dispersion in PBS. To study the biodistribution of the Ag S superdots, mice received a small incision in the neck skin to expose the right jugular vein. A polyethylene tubing catheter was inserted 2 mm in the caudal direction to infuse 100 mI_ of solution containing 1.5 mg/ml_ PEG-coated Ag S superdots dispersed in PBS. Three hours after infusion, mice were euthanized by isoflurane overdose and organs (liver, spleen, heart and lungs) were collected to obtain ex-vivo NIR-II images.
One additional mouse was anesthetized in order to check the potential thermal loading induced by laser with and without fur. In this case, the temperature at the skin surface was measured with an infrared thermographic camera (Fluke iT10). In vivo biocompatibility studies.
Four additional mice were intraperitoneally injected with 300 mI_ of a 500 pg/mL solution of Ag2S superdots in PBS. Four mice intraperitoneally injected with 300 mI_ of PBS were used as control group. The animals were housed in two separated cages in a room (23 ± 2°C) maintained on a 12/12 h light/dark cycle with free access to food and water.
Weight, food intake and surface temperature, as measured by an infrared thermographic camera (FLIR E-40), were analyzed in the awake mice on a daily basis for 2 weeks.

Claims

Claims
1. A method for manufacturing Ag2S nanoparticles comprising the following steps: a. Mixing a given amount of silver with a solvent comprising a mixture based on an i) organic long-chain molecule, comprising between 4 and 20 carbon atoms in length and comprising an amine group, and ii) DDT (1- dodecanethiol), or any other thiol based molecule with a boiling point of between 140 and 200°C, wherein the solvent mole fraction (xDDT) calculated as xDDT= (nDDT/(nDDT + organic long-chain molecule (such as nOLA))) is between 0.30 and 0.90;
b. submitting the reaction mixture of a) to a temperature between 80°C and 350°C in, preferably a closed atmosphere; and
c. collecting the nanoparticles.
2. The method of claim 1 , wherein the solvent mole fraction (xDDT) is between 0.55 and 0.65.
3. The method of claim 1 , wherein the solvent mole fraction (xDDT) is between 0.59 and 0.61.
4. The method of claim 1 , wherein the solvent mole fraction (xDDT) is 0.60.
5. The method of any of claims 1 to 4, wherein silver can be provided in any form selected from the list consisting of: Ag(DDTC), silver nitrate, silver dihydrocarbyl thiophosphate, silver dioctyl sulfosuccinate, silver thiobenzoate, silver acetate, silver dodecanoate, silver tetradecanoate and silver octadecenoate.
6. The method of any of claims 1 to 4, wherein the organic long-chain molecules are selected from the list consisting of octylamine, trioctylamine, dodecylamine, octadecylamine, and OLA (oleylamine).
7. The method of claim 1 , wherein the solvent mole fraction (xDDT) is 0.60, and the organic long-chain molecules is OLA (oleylamine).
8. The method of claim 7, wherein silver is provided in the form consisting of Ag(DDTC).
9. The method of any of claims 1 to 8, wherein the closed atmosphere is created by using a vacuum, preferably for about 10 min, to remove air and then filled with
N2.
10. The method of any of claims 1 to 9, wherein in step b) the mixture is heated to a temperature between 170°C and 210°C, still more preferably to a temperature about 190°C, under magnetic stirring, preferably with a heating rate of 20°C/min and under slow magnetic stirring.
11. The method of any of claims 1 to 10, wherein prior to step c) the reaction is cooled down by any suitable means, preferably by naturally cooling the reaction.
12. The method of any of claims 1 to 11 , wherein in step c) the nanoparticles are collected by the addition of ethanol, which reduces the colloidal stability of the nanoparticles, preferably by adding about 10 mL of ethanol to the raw product and centrifuging at about 10,000 rpm for 10 min, and preferably repeating this process twice.
13. The method of any of claims 1 to 12, wherein the resultant product of step c) is dispersed in chloroform and stored.
14. A method for manufacturing pegylated Ag2S nanoparticles comprising the following steps: a. adding a hydrophilic agent such as 11-mercaptoundecanoic acid (MUA), dihydrolipoic acid, 2,3 dimercaptosuccinic acid, mercaptopropionic acid, or cysteine, to a dispersion containing the Ag2S/Ag nanoparticles as obtained from the method of any of claims 1 to 13, preferably in chloroform at room temperature;
b. Precipitating and collecting the product of step a);
c. Covering the precipitates of step b) with PEG, preferably PEG-NH2, more preferably via EDC/NHS coupling; and
d. Collecting the nanoparticles.
15. Ag2S nanoparticles obtained or obtainable by the method of any of claims 1 to 13.
16. Ag2S nanoparticles obtained or obtainable by the method of any of claims 7 or 8.
17. Ag2S nanoparticles obtained or obtainable by the method of claim 14.
18. A composition comprising the nanoparticles of any of claims 15 to 17.
19. A composition as defined in claim 18 or the nanoparticles as defined in any of claims 15 to 17 for use as an in vivo imaging agent.
20. A composition as defined in claim 18 or the nanoparticles as defined in any of claims 15 to 17 for use as an in vitro imaging agent.
21. A method of manufacturing Ag2S nanoparticles comprising the following steps: a. Treating or irradiating Ag2S nanoparticles as defined in any of claims 15 to 17 with an ultra-fast laser, wherein such treatment is performed by dispersing the Ag2S nanoparticles in chloroform, dichloromethane, dichloroethane, trichloroethane or in any organic solvent comprising chlorine; and
b. Optionally collecting the nanoparticles.
22. The method of claim 21 , wherein such treatment is performed by dispersing the Ag2S nanoparticles in chloroform.
23. The method of claim 21 or 22, wherein after step a) or b) the nanoparticles are further subjected to a ligand exchange reaction to generate hydrophilic Ag2S nanoparticles, wherein the ion exchange reaction is carried out by mixing hydrophobic Ag2S nanoparticles with an equivalent amount or an excess amount of a hydrophilic molecule comprising a thiol group so that the surface of the Ag2S nanoparticles are functionalized by the hydrophilic group thus obtaining or resulting in hydrophilic particles.
24. The method of any of claims 21 to 23, wherein the nanoparticles are irradiated or treated using an ultra-fast laser with a power density of less than 40W/cm2, with pulses of less than 500 femto-seconds, and at preferably a frequency of 1 kHz for preferably approximately 10 minutes.
25. The method of any of claims 21 to 23, wherein the nanoparticles are irradiated or treated using an ultra-fast laser with a power density of between 6 and 10 W/cm2, with pulses of about 50 femto-seconds, and at preferably a frequency of 1 kHz for preferably approximately 10 minutes.
26. Ag2S nanoparticles obtained or obtainable by the method of any of claims 21 to 25.
27. A composition comprising the nanoparticles of claim 26.
28. A composition as defined in claim 27 or the nanoparticles as defined in claim 26, for use as an in vivo imaging agent.
29. A composition as defined in claim 27 or the nanoparticles as defined in claim 26, for use as as an in vitro imaging agent.
PCT/EP2020/050939 2019-01-15 2020-01-15 Ag2s nanoparticles and methods of production thereof Ceased WO2020148347A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201900006A ES2773946B2 (en) 2019-01-15 2019-01-15 Super fluorescent AG2S nanoparticles in the near infrared region and method of obtaining
ESP201900006 2019-01-15

Publications (1)

Publication Number Publication Date
WO2020148347A1 true WO2020148347A1 (en) 2020-07-23

Family

ID=69174486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/050939 Ceased WO2020148347A1 (en) 2019-01-15 2020-01-15 Ag2s nanoparticles and methods of production thereof

Country Status (2)

Country Link
ES (1) ES2773946B2 (en)
WO (1) WO2020148347A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116754508A (en) * 2023-07-19 2023-09-15 南京理工大学 A rapid method for detecting the purity of pentazole silver

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083647A1 (en) * 2011-05-30 2016-03-24 Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences Preparation Method of Near-Infrared Silver Sulfide Quantum Dots
CN106753344A (en) * 2016-11-25 2017-05-31 清华大学 Silver sulfide quantum dot and preparation method and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083647A1 (en) * 2011-05-30 2016-03-24 Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences Preparation Method of Near-Infrared Silver Sulfide Quantum Dots
CN106753344A (en) * 2016-11-25 2017-05-31 清华大学 Silver sulfide quantum dot and preparation method and application

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEM. PHYS. LETT., vol. 229, 1994, pages 333
DATABASE WPI Week 201750, 31 May 2017 Derwent World Patents Index; AN 2017-40536W, XP002798659 *
KAI CHENG ET AL: "High-Security Nanocluster for Switching Photodynamic Combining Photothermal and Acid-Induced Drug Compliance Therapy Guided by Multimodal Active-Targeting Imaging", ADVANCED FUNCTIONAL MATERIALS, vol. 28, no. 36, 1 September 2018 (2018-09-01), DE, pages 1803118, XP055684517, ISSN: 1616-301X, DOI: 10.1002/adfm.201803118 *
LU FENG ET AL: "Facile one-pot synthesis of monodispersed NIR-II emissive silver sulfide quantum dots", INORGANIC CHEMISTRY COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 106, 10 June 2019 (2019-06-10), pages 233 - 239, XP085741117, ISSN: 1387-7003, [retrieved on 20190610], DOI: 10.1016/J.INOCHE.2019.06.013 *
REMPEL S V ET AL: "The irradiation influence on the properties of silver sulfide (Ag2S) colloidal nanoparticles", PHYSICS OF THE SOLID STATE, AMERICAN INSTITUTE OF PHYSICS, WOODBURY, NY, US, vol. 59, no. 8, 25 August 2017 (2017-08-25), pages 1629 - 1636, XP036306556, ISSN: 1063-7834, [retrieved on 20170825], DOI: 10.1134/S1063783417080224 *
YAN ZHANG, YEJUN ZHANG, GUOSONG HONG, WEI HE, KUN ZHOU, KAI YANG, FENG LI, GUANGCUN CHEN, ZHUANG LIU, HONGJIE DAI, QIANGBIN WANG: "Biodistribution, pharmacokinetics and toxicology of Ag2S near-infrared quantum dots in mice.", BIOMATERIALS, vol. 34, 14 February 2013 (2013-02-14), pages 3639 - 3646, XP028985994, DOI: 10.1016/j.biomaterials.2013.01.089 *
YAPING DU ET AL: "Near-Infrared Photoluminescent Ag 2 S Quantum Dots from a Single Source Precursor", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 5, 10 February 2010 (2010-02-10), US, pages 1470 - 1471, XP055684943, ISSN: 0002-7863, DOI: 10.1021/ja909490r *
YAPING DU ET AL: "Supporting Information Near-Infrared Photoluminescent Ag 2 S Quantum Dots from a Single Source Precursor", 10 February 2010 (2010-02-10), XP055684944, Retrieved from the Internet <URL:https://pubs.acs.org/doi/suppl/10.1021/ja909490r/suppl_file/ja909490r_si_001.pdf> [retrieved on 20200409] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116754508A (en) * 2023-07-19 2023-09-15 南京理工大学 A rapid method for detecting the purity of pentazole silver

Also Published As

Publication number Publication date
ES2773946A1 (en) 2020-07-15
ES2773946B2 (en) 2021-03-08

Similar Documents

Publication Publication Date Title
Santos et al. Ultrafast photochemistry produces superbright short-wave infrared dots for low-dose in vivo imaging
US20220001032A1 (en) Coated up-conversion nanoparticles
Wang et al. Recent progress in biomedical applications of persistent luminescence nanoparticles
Singh et al. Biocompatible fluorescent carbon quantum dots prepared from beetroot extract for in vivo live imaging in C. elegans and BALB/c mice
Morselli et al. Luminescent copper indium sulfide (CIS) quantum dots for bioimaging applications
Torrisi et al. Laser-generated bismuth nanoparticles for applications in imaging and radiotherapy
USRE43944E1 (en) Upconversion fluorescent nano-structured material and uses thereof
CA2702919C (en) Use of lanthanide-based nanoparticles as radiosensitizing agents
Chen et al. Preparation and photodynamic therapy application of NaYF4: Yb, Tm–NaYF4: Yb, Er multifunctional upconverting nanoparticles
Yang et al. A biomineral-inspired approach of synthesizing colloidal persistent phosphors as a multicolor, intravital light source
Zahedifar et al. Afterglow properties of CaF2: Tm nanoparticles and its potential application in photodynamic therapy
RU2602698C2 (en) ?-form zinc-phthalocyanine nanowires having enhanced water solubility and water dispersibility, composite of an ?-form zinc- phthalocyanine nanowire/phenothiazine, and method for preparing thereof
KR101267313B1 (en) Photothermal ablation of cancer cells using organic nanoparticles
Deng et al. Forming highly fluorescent near-infrared emitting PbS quantum dots in water using glutathione as surface-modifying molecule
Meng et al. Rare earth-doped nanocrystals for bioimaging in the near-infrared region
Yang et al. Short-wave near-infrared emissive GdPO 4: Nd 3+ theranostic probe for in vivo bioimaging beyond 1300 nm
Wang et al. AlPcS-loaded gold nanobipyramids with high two-photon efficiency for photodynamic therapy in vivo
Caires et al. A carboxymethylcellulose-mediated aqueous colloidal process for building plasmonic–excitonic supramolecular nanoarchitectures based on gold nanoparticles/ZnS quantum emitters for cancer theranostics
WO2020148347A1 (en) Ag2s nanoparticles and methods of production thereof
KR101507645B1 (en) Organic/inorganic nanocomposite for diagnosis and treatment of cancer
Solodov et al. Hydrophilization of core-shell NaYF4: Yb/Er@ NaGdF4: Ce/Tb nanostructures using polyethylenimine for multimodal imaging
Idowu et al. Photophysical behavior of fluorescent nanocomposites of phthalocyanine linked to quantum dots and magnetic nanoparticles
US11401232B2 (en) Modified chromium-doped zinc gallate nanocube, its preparation method and uses thereof
CN116554859A (en) Near infrared light excited ultrafine nano-cluster and preparation method and application thereof
Ibrahim et al. Wet chemical synthesis of TGA capped Ag 2 S nanoparticles and their use for fluorescence imaging and temperature sensing in living cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20701011

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20701011

Country of ref document: EP

Kind code of ref document: A1